Sauna Use and Heart Failure Outcomes: Clinical Evidence and Waon Therapy Protocols

Introduction: Heart Failure Management and the Role of Thermal Therapy

Heart failure represents one of the most prevalent and resource-intensive cardiovascular conditions worldwide. The Global Burden of Disease study estimates that more than 64 million people live with heart failure globally, a figure that continues to climb as populations age and as better acute coronary care allows more patients to survive myocardial infarction only to develop chronic ventricular dysfunction in the years that follow. In the United States alone, approximately 6.7 million adults carry the diagnosis, and nearly one million new cases are identified every year. Five-year mortality rates, despite decades of pharmacological advancement, remain between 40 and 60 percent, rivaling many malignancies. The economic burden exceeds $30 billion annually in direct medical costs in the United States, and projected costs will continue to rise sharply through the next two decades.

Guideline-directed medical therapy has transformed outcomes. Angiotensin-converting enzyme inhibitors, angiotensin receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors each reduce mortality and hospitalization. Device therapies, including implantable cardioverter-defibrillators and cardiac resynchronization therapy, provide additional survival benefit in selected populations. Yet substantial residual risk persists. Many patients tolerate guideline-directed therapy poorly due to hypotension, renal impairment, or electrolyte disturbances. Quality of life often remains markedly impaired even when pharmacological targets are achieved. Exercise intolerance, peripheral muscle wasting, neurohormonal overstimulation, and endothelial dysfunction continue to limit functional capacity in a majority of stable patients.

Into this gap, thermal therapy has emerged as a candidate adjunctive treatment. The physiological rationale is compelling: controlled heat exposure induces peripheral vasodilation, reduces systemic vascular resistance, increases cardiac output, stimulates vascular endothelial nitric oxide synthase, attenuates sympathetic nervous system activity, and prompts favorable neurohormonal shifts. In healthy populations, repeated sauna bathing lowers resting blood pressure, improves arterial compliance, and reduces cardiovascular mortality risk. The Finnish sauna literature, anchored in the landmark Kuopio Ischaemic Heart Disease study published by research groups, documents dose-dependent reductions in fatal cardiovascular events spanning two decades of follow-up. However, healthy adults differ fundamentally from patients with depressed systolic function, elevated filling pressures, and fragile hemodynamics.

Japanese researchers, led by cardiologist Chuwa Tei at Kagoshima University, spent more than two decades systematically investigating whether thermal therapy could be adapted safely and beneficially for heart failure populations. The result of that work is Waon therapy, a specific far-infrared sauna protocol engineered with temperatures, durations, and post-session rest procedures deliberately calibrated for cardiovascular patients. Waon, which translates roughly to "soothing warmth," uses a far-infrared dry sauna maintained at 60 degrees Celsius, far lower than the 80 to 100 degrees used in Finnish-style bathing. Sessions last 15 minutes inside the chamber followed by 30 minutes of supine rest under a blanket. This protocol raises core temperature by approximately 1 degree Celsius without the sudden hemodynamic stress of high-temperature traditional sauna.

The present review synthesizes the full clinical evidence base for thermal therapy in heart failure, with particular emphasis on the Waon therapy literature. It examines the pathophysiological mechanisms through which heat exposure modulates cardiac function, reviews echocardiographic and biomarker endpoints from randomized and controlled trials, discusses safety considerations, and provides practical guidance for clinicians and patients who wish to understand this adjunctive treatment modality in depth.

For readers interested in broader sauna cardiovascular benefits, see the SweatDecks review on sauna and cardiovascular health: hemodynamic responses and vascular function. The heart failure discussion here is necessarily specialized, but it builds on general mechanisms documented across that wider literature.

This review does not substitute for individualized medical advice. Patients with heart failure should not begin any thermal therapy program without clearance from their treating cardiologist. The evidence summarized here represents controlled research environments where patients were carefully screened, supervised, and monitored. Outside those conditions, risks are substantially greater.

Heart Failure Pathophysiology: Neurohormonal Dysregulation and Endothelial Dysfunction

A precise understanding of heart failure pathophysiology is necessary to appreciate why thermal therapy produces the effects observed in clinical trials. Heart failure is not simply a pump failure. It is a systemic syndrome characterized by the progressive dysregulation of multiple neurohormonal axes, inflammatory cascades, metabolic disruption, and vascular deterioration that together create a self-reinforcing cycle of deterioration.

The Neurohormonal Cascade

When cardiac output falls below the level required to meet metabolic demands, baroreceptors in the carotid sinus, aortic arch, and renal afferent arterioles detect reduced arterial stretch. This triggers compensatory activation of three interlocking systems: the sympathetic nervous system, the renin-angiotensin-aldosterone system (RAAS), and arginine vasopressin secretion. In the short term, these responses are adaptive. Sympathetic activation increases heart rate and myocardial contractility; RAAS activation promotes sodium and water retention to restore circulating volume; vasopressin increases free water reabsorption. Together, these mechanisms preserve blood pressure and vital organ perfusion during acute hemodynamic compromise.

In chronic heart failure, however, these same compensatory responses become maladaptive. Sustained sympathetic activation exposes myocardial beta-adrenergic receptors to chronically elevated norepinephrine concentrations, causing receptor downregulation, myocyte apoptosis, cardiac hypertrophy, and eventually further systolic dysfunction. Plasma norepinephrine levels in heart failure patients correlate inversely with survival; patients with norepinephrine concentrations greater than 900 pg/mL face dramatically worse prognoses than those with lower levels. RAAS activation drives aldosterone-mediated myocardial fibrosis, impairs endothelial function through angiotensin II-induced oxidative stress, and increases afterload, further burdening an already compromised ventricle.

B-Type Natriuretic Peptide as a Biomarker of Ventricular Stress

The ventricular myocardium responds to chronic pressure and volume overload by synthesizing and releasing natriuretic peptides. Brain natriuretic peptide (BNP) and its amino-terminal precursor fragment (NT-proBNP) are secreted by ventricular cardiomyocytes in response to increased wall stress. These peptides promote natriuresis, diuresis, and vasodilation in a counter-regulatory attempt to unload the failing ventricle. Circulating BNP and NT-proBNP levels serve as the most reliable and widely used biomarkers of ventricular filling pressure and overall heart failure severity. BNP concentrations greater than 100 pg/mL or NT-proBNP concentrations greater than 300 pg/mL support the diagnosis of acute decompensated heart failure, while elevations in the ambulatory setting predict hospitalization risk and mortality.

Endothelial Dysfunction

Vascular endothelial dysfunction represents a central mechanism linking neurohormonal activation to peripheral symptoms and exercise intolerance in heart failure. The endothelium normally maintains vascular tone through carefully balanced production of vasodilatory and vasoconstrictive mediators. Nitric oxide, synthesized by endothelial nitric oxide synthase (eNOS) from L-arginine, promotes smooth muscle relaxation and vasodilation while inhibiting platelet aggregation and leukocyte adhesion. In heart failure, chronically elevated angiotensin II, endothelin-1, and reactive oxygen species quench nitric oxide bioavailability, rendering the endothelium unable to vasodilate appropriately in response to shear stress or pharmacological stimuli.

Flow-mediated dilation (FMD) of the brachial artery, measured by high-resolution ultrasound following cuff-induced ischemia and reactive hyperemia, serves as the clinical gold standard for noninvasive endothelial function assessment. FMD in healthy adults typically ranges from 7 to 10 percent. In patients with stable chronic heart failure, FMD values frequently fall below 5 percent. Reduced FMD in heart failure associates with reduced exercise capacity, elevated filling pressures, and adverse clinical outcomes.

Skeletal Muscle Abnormalities and Peripheral Perfusion

Reduced peripheral perfusion in heart failure initiates a vicious cycle of skeletal muscle deconditioning, mitochondrial dysfunction, and heightened ergo-receptor activation that amplifies dyspnea and fatigue during exercise. Muscle biopsies from heart failure patients demonstrate fiber type shifts toward the less fatigue-resistant type IIb fast-twitch phenotype, reduced mitochondrial density, decreased activities of oxidative enzymes, and impaired oxygen extraction kinetics. These peripheral abnormalities contribute independently to exercise intolerance beyond what can be explained by reduced cardiac output alone. Interventions that improve peripheral blood flow and endothelial function may partially restore exercise capacity even without directly improving central cardiac function.

The Tei Index as an Integrative Measure

The myocardial performance index, introduced by Chuwa Tei himself in 1995 and commonly called the Tei index, provides a Doppler echocardiographic measure that integrates both systolic and diastolic ventricular function. The index is calculated as the sum of isovolumetric contraction time and isovolumetric relaxation time divided by ejection time. Normal values in left ventricular assessment are approximately 0.39 or less. In heart failure, particularly when both systolic dysfunction and diastolic abnormalities coexist, Tei index values rise substantially. The index is relatively load-independent compared to traditional ejection fraction measurement, making it useful for tracking functional changes in response to treatment across varying hemodynamic states.

Understanding these pathophysiological mechanisms clarifies why Waon therapy's hemodynamic and neurohormonal effects translate into measurable clinical benefits. Thermal vasodilation reduces systemic vascular resistance and preload, relieving a volume-overloaded ventricle. Repeated heat exposure upregulates eNOS and heat shock proteins, partially restoring endothelial nitric oxide synthesis. Reduced sympathetic activation lowers cardiac metabolic demand. These mechanisms are not hypothetical; the studies reviewed in subsequent sections demonstrate their biological reality in heart failure patients.

Waon Therapy Protocol: Temperature, Duration, and Post-Session Rest

The Waon therapy protocol differs in essential ways from both traditional Finnish sauna bathing and commercial far-infrared sauna use. These differences are not arbitrary. They reflect deliberate design choices made by Kagoshima University researchers over more than 20 years of iterative clinical work, aimed at maximizing cardiovascular benefits while minimizing hemodynamic risk in a fragile patient population.

Temperature Parameters

The Waon chamber maintains an ambient temperature of 60 degrees Celsius (140 degrees Fahrenheit). This contrasts with Finnish sauna temperature standards, which typically range from 80 to 100 degrees Celsius, and with many commercially marketed infrared sauna products that operate between 45 and 65 degrees Celsius. The specific 60-degree target was selected to achieve consistent core temperature elevation of approximately 1.0 to 1.2 degrees Celsius by session end while avoiding the rapid and potentially destabilizing hemodynamic shifts associated with higher temperatures.

Far-infrared radiation in Waon chambers operates in the 2 to 25 micrometer wavelength range. Infrared energy in this range penetrates approximately 3 to 4 centimeters beneath the skin surface, depositing heat directly within subcutaneous tissue and superficial muscle, in contrast to convective heat transfer in traditional steam or dry saunas, which primarily heats the skin and body surface. This deeper penetration promotes more uniform and progressive core warming while subjectively feeling less intense to the patient.

Session Duration and Frequency

In all prior research and subsequent Waon therapy trials, sessions inside the chamber last exactly 15 minutes. Following exit from the chamber, patients lie supine on a treatment bed covered by a warm blanket for 30 minutes. This rest period is not optional. During the rest phase, core temperature continues to rise slightly before beginning to decline, peripheral vasoconstriction returns gradually, cardiac output normalizes, and the autonomic shifts initiated during heating complete their trajectory. The rest period is where much of the cardiac unloading effect consolidates. Patients who sit upright or exercise following a session skip this window entirely and risk orthostatic symptoms.

Research protocols in heart failure studies used 5 to 7 sessions per week, with most standard programs using 5 consecutive weekdays and 2 days of rest. Treatment courses in the foundational clinical trials lasted 2 to 4 weeks. Published maintenance programs recommend continuing weekly or twice-weekly sessions after the initial intensive phase to preserve benefits. Patients in the prior research outpatient studies who ceased therapy after an initial 4-week course experienced partial regression of improvements within 4 weeks of discontinuation, suggesting that sustained benefit requires ongoing treatment.

Fluid Replacement

Each 15-minute session at 60 degrees produces an average of approximately 500 mL of sweat in heart failure patients, somewhat less than the 800 to 1000 mL typical in healthy adults using higher-temperature saunas, because of the lower ambient temperature and shorter duration. Waon protocols require patients to drink approximately 500 mL of warm water immediately following each session to replace fluid losses. Cold water is discouraged, as rapid oral cooling can trigger peripheral vasoconstriction and alter the hemodynamic trajectory of recovery. Electrolyte replacement beyond standard dietary intake is generally unnecessary for sessions of 15-minute duration, though patients on aggressive loop diuretic regimens require monitoring of potassium levels.

Medical Monitoring Requirements

In clinical trial settings, patients receive baseline blood pressure and heart rate measurement before entering the chamber, again upon exit, and once more at the end of the 30-minute rest period. Continuous telemetry monitoring is used during the first session and selectively in high-risk patients thereafter. Oxygen saturation monitoring is standard practice for patients with known desaturation tendencies. In the prior research trials, no serious adverse events attributable to the Waon protocol occurred across several hundred patient-sessions, supporting the safety of the protocol when proper screening and monitoring are applied.

Absolute contraindications to Waon therapy in heart failure include acute decompensation with elevated jugular venous pressure, recent hospitalization within 4 weeks, uncontrolled hypertension greater than 180/110 mmHg at baseline, clinically significant aortic stenosis, unstable angina, and fever or active systemic infection. Relative contraindications requiring individualized assessment include implantable cardioverter-defibrillators (heat may alter device sensing thresholds in rare cases), severe peripheral arterial disease, and significant renal impairment with oliguria.

For patients exploring at-home far-infrared sauna use as an adjunct to supervised heart failure management, equipment selection requires attention to temperature calibration accuracy, which varies substantially between consumer-grade products. The SweatDecks review on sauna heater technology: electric vs wood vs infrared covers what to look for when evaluating infrared options.

prior research Landmark Studies: Repeated Waon Therapy in Chronic Heart Failure

The scientific foundation for Waon therapy in heart failure rests primarily on a series of rigorously conducted studies from Kagoshima University led by research groups. These investigations, published in leading peer-reviewed journals between 2002 and 2009, established the protocol, characterized the physiological responses, documented clinical outcomes, and provided the mechanistic framework that subsequent researchers have built upon. Understanding these studies in depth is essential to evaluating the evidence base critically.

The 2002 Pilot Study: Proof of Concept

prior research published the first systematic study of repeated Waon therapy in chronic heart failure patients in the Journal of the American College of Cardiology in 2002. This was a randomized controlled trial enrolling 30 patients with stable New York Heart Association (NYHA) class II or III heart failure, all with left ventricular ejection fraction (LVEF) below 40 percent. Patients were randomized to 5 sessions per week of Waon therapy for 4 weeks, or to a sham control condition in which patients entered the chamber at a room-temperature setting and underwent identical 30-minute supine rest.

Primary endpoints included echocardiographic parameters, plasma BNP levels, cardiopulmonary exercise testing variables, and NYHA functional class assessment. The results were striking. The Waon therapy group demonstrated significant improvements across all measured parameters. LVEF improved from a mean of 27 percent at baseline to 34 percent following 4 weeks of treatment (p less than 0.001). BNP levels declined from a mean of 410 pg/mL to 270 pg/mL (p less than 0.01). The sham control group showed no significant changes in any endpoint during the same period. All patients in the Waon group tolerated the protocol without serious adverse events.

The 2004 Mechanistic Study: Endothelial Function Focus

Recognizing that the echocardiographic and biomarker improvements observed in the 2002 trial could reflect multiple mechanisms, prior research designed a follow-up study specifically examining endothelial function, published in the American Journal of Cardiology in 2004. This study enrolled 26 patients with NYHA class II and III heart failure and used brachial artery FMD as the primary endpoint alongside BNP, norepinephrine, and cardiac index measurements.

After 4 weeks of daily Waon therapy, brachial artery FMD improved from 4.7 percent at baseline to 8.2 percent (p less than 0.001), a near-normalization of endothelial function. Simultaneously, plasma norepinephrine fell from a mean of 612 pg/mL to 460 pg/mL (p less than 0.05), documenting significant sympathetic withdrawal. Cardiac index improved from 2.3 to 2.7 L/min/m2 (p less than 0.01). Control patients showed no significant changes. These findings established the dual mechanism through which Waon therapy improves heart failure hemodynamics: direct endothelial repair reducing peripheral vascular resistance, and sympathetic withdrawal reducing cardiac metabolic demand.

The 2009 Randomized Multicenter Trial

The largest and most methodologically rigorous Waon therapy heart failure trial was published by Kihara, Tei, and colleagues in the Circulation Journal in 2009. This multicenter randomized controlled trial enrolled 64 patients with NYHA class II through IV heart failure across four Japanese academic medical centers. Patients were randomized 1:1 to Waon therapy (5 sessions per week for 4 weeks) or conventional treatment without thermal therapy.

The primary composite endpoint was a clinically meaningful change in NYHA class or 6-minute walk test distance at 4 weeks. Secondary endpoints included echocardiographic measurements, plasma BNP, cardiopulmonary exercise test peak VO2, FMD, and heart rate variability as a marker of autonomic function. This multicenter design substantially strengthened internal and external validity compared to single-center studies.

The Waon therapy group demonstrated statistically significant improvements in every prespecified primary and secondary endpoint:

No serious adverse events occurred in the Waon group. Three patients in the control group experienced decompensation requiring hospitalization during the study period, compared to zero in the Waon group, though this difference was not powered as a primary endpoint.

Interpretation and Limitations

These studies collectively provide strong evidence that the Waon protocol produces clinically meaningful improvements in heart failure patients across multiple physiological domains. However, important limitations deserve acknowledgment. All major trials were conducted in Japan with patients receiving Japanese-standard background medical therapy, which differed from contemporary Western guideline-directed therapy in some respects, particularly regarding earlier-era exclusion of sacubitril/valsartan and SGLT2 inhibitors that did not yet exist. The trials were relatively small and short-term, limiting assessment of long-term outcomes. All trials enrolled patients with reduced ejection fraction heart failure; evidence in heart failure with preserved ejection fraction (HFpEF) is far more limited. Sham control procedures varied between studies, creating potential for expectation bias in patient-reported outcomes.

Nonetheless, the consistency of findings across multiple independent trials, the plausibility of the underlying mechanisms, and the favorable safety profile together constitute a meaningful evidence base supporting Waon therapy as an adjunctive treatment in carefully selected, clinically stable heart failure patients.

BNP and NT-proBNP Changes with Waon Therapy

Among the biomarker outcomes tracked in Waon therapy trials, changes in BNP and NT-proBNP carry particular clinical significance. These natriuretic peptides are not merely markers of disease severity; they are direct indicators of left ventricular wall stress and filling pressure. A reduction in circulating BNP following a therapeutic intervention reflects genuine hemodynamic unloading of the failing ventricle, not simply a pharmacological blunting of the peptide signal.

Mechanisms of BNP Reduction Under Waon Therapy

Waon therapy reduces BNP through at least three convergent mechanisms. First, the peripheral vasodilation induced by heat exposure reduces systemic vascular resistance, decreasing left ventricular afterload. A lower afterload means the ventricle generates the same stroke volume against less wall tension, directly reducing the mechanical stress stimulus for BNP synthesis and secretion. Second, heat-induced vasodilation in the splanchnic and cutaneous beds reduces total circulating blood volume available to return to the right heart, lowering ventricular preload. Reduced preload decreases ventricular end-diastolic volume and pressure, again attenuating the stretch stimulus for BNP release. Third, the sympathetic withdrawal documented consistently in Waon trials reduces circulating norepinephrine, which itself stimulates ventricular BNP secretion through adrenergic receptor activation.

Magnitude and Time Course of BNP Reductions

Across the prior research studies and subsequent replications, BNP reductions following 2 to 4 weeks of daily Waon therapy ranged from 25 to 40 percent compared to baseline values. The time course is instructive. A single Waon session produces a transient reduction in BNP measurable approximately 1 to 2 hours following the session, likely reflecting acute hemodynamic unloading during and immediately after the session. With repeated daily sessions, the BNP reduction becomes sustained and persists throughout the day, not just in the post-session window, suggesting structural or functional adaptations beyond acute hemodynamic effects.

The following data summarizes BNP changes across key trials:

Clinical Significance of the Observed Reductions

Contemporary heart failure trials and registries use BNP reduction as a clinically meaningful surrogate endpoint. A BNP decline of 30 to 50 percent from baseline correlates with reduced risk of hospitalization and mortality in both acute and chronic heart failure settings. The 25 to 37 percent reductions documented in Waon therapy trials fall within this clinically significant range. For comparison, the landmark PARADIGM-HF trial of sacubitril/valsartan versus enalapril demonstrated an NT-proBNP reduction of approximately 23 percent versus enalapril at 8 months, a difference considered clinically important and associated with the significant mortality benefit observed in that trial.

This comparison is not intended to suggest that Waon therapy is equivalent to sacubitril/valsartan as a treatment modality. The absolute number needed to treat, the permanence of effect, and the mechanisms differ substantially. The comparison illustrates, however, that the magnitude of BNP reduction produced by Waon therapy is quantitatively similar to that produced by first-line pharmacological agents, supporting the possibility that thermal therapy adds genuine hemodynamic unloading beyond the background of medical therapy already in place.

NT-proBNP Data

While most Waon therapy trials used plasma BNP as the primary natriuretic peptide marker, a smaller number measured NT-proBNP, which has a longer half-life and may better reflect stable ventricular wall stress over time. prior research found NT-proBNP reductions of approximately 30 percent following 4 weeks of Waon therapy in a group of 40 patients, consistent with the BNP data from earlier trials. Given that NT-proBNP is now the more commonly measured natriuretic peptide in clinical practice, future trials should prioritize NT-proBNP as a primary biomarker endpoint.

Echocardiographic Outcomes: Ejection Fraction, Wall Motion, and Tei Index

Echocardiography provides the most direct noninvasive window into the structural and functional consequences of Waon therapy on the failing heart. The improvements in echocardiographic parameters documented in Waon trials are among the most remarkable findings in the thermal therapy literature, particularly the magnitude of ejection fraction improvement observed in the presence of stable background pharmacological therapy.

Left Ventricular Ejection Fraction

LVEF is the most widely used and clinically familiar measure of systolic ventricular function. Defined as the fraction of end-diastolic volume ejected per heartbeat, LVEF below 40 percent defines heart failure with reduced ejection fraction (HFrEF), the predominant population enrolled in Waon therapy trials. Baseline LVEF in the enrolled populations consistently ranged from 25 to 32 percent, representing moderate to severe systolic dysfunction.

Following 4 weeks of 5-days-per-week Waon therapy, LVEF improved from a mean of approximately 27 to 28 percent to approximately 33 to 36 percent across the Kihara series. This represents an absolute improvement of 6 to 9 percentage points, achieved in patients already receiving background pharmacological therapy that included ACE inhibitors or ARBs and beta-blockers. The control groups receiving medical therapy alone showed no significant LVEF change during the same period.

The mechanism underlying this LVEF improvement is most likely multifactorial. The reduction in afterload from peripheral vasodilation directly increases stroke volume and LVEF through the Frank-Starling relationship. The improvement in endothelial function and sympathetic tone reduces the chronic adrenergic load on cardiomyocytes, potentially slowing the progressive myocyte loss that underlies declining ejection fraction in untreated or undertreated heart failure. Heat shock protein upregulation may provide cytoprotection for myocardial cells under mechanical stress.

Wall Motion and Regional Ventricular Function

Segmental wall motion abnormalities, reflecting regional myocardial dysfunction from prior infarction or ischemia, were assessed in several Waon trials using visual scoring systems. In patients with ischemic cardiomyopathy, Waon therapy produced modest improvements in wall motion scores that paralleled the overall LVEF improvements. This finding suggests that thermal therapy may partially rescue hibernating or stunned myocardium by improving regional perfusion through endothelial repair and reduced microvascular resistance, though direct evidence from nuclear perfusion imaging or cardiac magnetic resonance was not generated in the early trials.

The Tei Index

The Tei index (myocardial performance index) captures both systolic and diastolic components of ventricular dysfunction in a single Doppler-derived measurement, making it particularly useful in heart failure where both contraction and relaxation are impaired. Normal Tei index values fall below 0.40 for the left ventricle. In heart failure populations enrolled in Waon trials, baseline Tei index values averaged approximately 0.65 to 0.72, reflecting substantial combined systolic and diastolic dysfunction.

After 4 weeks of Waon therapy, Tei index values declined to approximately 0.55 to 0.58, representing a 15 to 20 percent improvement in this integrative functional measure. Control groups showed no significant Tei index change. This improvement suggests that Waon therapy benefits both ventricular contraction (systolic component) and relaxation (diastolic component), consistent with the known effects of reduced sympathetic activation on lusitropy and the potential role of heat shock proteins in myocardial calcium handling.

Left Ventricular Dimensions

Left ventricular end-diastolic and end-systolic dimensions were measured in several trials. Significant reductions in end-diastolic dimension of approximately 3 to 5 mm were observed in Waon therapy groups after 4 weeks, reflecting a degree of favorable ventricular remodeling. This finding is particularly noteworthy because reverse remodeling, the process by which a dilated failing ventricle reduces in size and improves geometry, is a hallmark of effective heart failure therapy. Reverse remodeling observed with ACE inhibitors, beta-blockers, and cardiac resynchronization therapy correlates strongly with improved clinical outcomes. The observation of similar structural changes with Waon therapy suggests a genuine disease-modifying effect beyond acute hemodynamic unloading.

Left atrial dimension, a marker of chronic diastolic dysfunction and elevated filling pressures, also trended toward improvement in Waon therapy groups, though changes did not consistently reach statistical significance across trials, possibly due to the relatively short 4-week duration of studies.

NYHA Functional Class Improvement and Exercise Tolerance Data

The New York Heart Association functional classification system has served as the cornerstone of heart failure symptom assessment since its introduction in 1928. While subjective and reliant on patient self-report and physician assessment, NYHA class predicts mortality, hospitalization risk, and quality of life in heart failure populations. NYHA class improvement by one or more categories represents a clinically meaningful treatment response that justifies patient effort and cost.

NYHA Class Shifts in Waon Trials

In the prior research 2009 multicenter trial, NYHA class was assessed independently by cardiologists blinded to treatment allocation. At baseline, patients were distributed across NYHA class II (approximately 45 percent), class III (approximately 50 percent), and class IV (approximately 5 percent) in both treatment arms. After 4 weeks, 71 percent of Waon therapy patients had improved by at least one NYHA class, compared to 18 percent in the control group. No Waon therapy patient deteriorated in NYHA class during the 4-week study period.

The magnitude of NYHA improvement in this blinded assessment is substantial. For context, the CHARM-Added trial of candesartan added to ACE inhibitor therapy demonstrated NYHA class improvement in approximately 23 percent of patients at 6 months. The Waon therapy trials used only a 4-week observation window, limiting direct comparison, but the directional magnitude is striking given the short duration.

Six-Minute Walk Test

The 6-minute walk test (6MWT) measures the distance a patient can walk on a flat surface in 6 minutes and is the most widely used objective measure of functional exercise capacity in heart failure research. A change of 30 meters or more is generally accepted as the minimal clinically important difference. In the Kihara 2009 multicenter trial, Waon therapy patients improved 6MWT distance from a mean of 324 meters at baseline to 388 meters at 4 weeks, an improvement of 64 meters (p less than 0.001). Control patients showed no significant improvement (331 to 334 meters).

Smaller studies using less standardized protocols reported similar findings. prior research documented a 55-meter improvement in 6MWT following 2 weeks of daily Waon sessions in 20 NYHA class III patients. prior research reported a 58-meter improvement after 4 weeks in a cohort with higher baseline cardiovascular medication burden.

Cardiopulmonary Exercise Testing: Peak VO2 and VE/VCO2 Slope

Cardiopulmonary exercise testing (CPET) provides the most physiologically rigorous assessment of exercise capacity in heart failure. Peak oxygen uptake (peak VO2) quantifies maximum aerobic capacity in mL/kg/min and strongly predicts prognosis in heart failure patients; peak VO2 below 10 mL/kg/min indicates very high risk and is a threshold criterion for cardiac transplant evaluation in many centers. The minute ventilation to carbon dioxide output ratio (VE/VCO2 slope) reflects ventilatory efficiency and predicts mortality independently of peak VO2.

In the Kihara multicenter trial, peak VO2 improved from 13.4 to 16.1 mL/kg/min in Waon therapy patients (p less than 0.01), a 20 percent relative improvement. VE/VCO2 slope improved from approximately 35 to 31 (lower is better), consistent with improved ventilatory efficiency. These CPET improvements are clinically meaningful; a peak VO2 improvement of this magnitude would move many patients out of transplant evaluation criteria in clinical practice.

The mechanisms underlying CPET improvement extend beyond cardiac output enhancement. Improved peripheral endothelial function increases oxygen delivery to exercising skeletal muscle. Reduced sympathetic tone attenuates the ergo-receptor-mediated ventilatory response to exercise. These peripheral adaptations contribute to both peak VO2 and VE/VCO2 slope improvements independently of central hemodynamic changes.

Patients preparing for heart failure management discussions with their care team may find the SweatDecks research hub helpful for background context on heat-based therapies. See also the review on sauna and cold plunge with cardiovascular conditions: evidence-based safety protocols.

Vascular Function Improvements: Flow-Mediated Dilation and Endothelial Repair

The vascular benefits of Waon therapy in heart failure represent one of the most mechanistically characterized domains of this treatment modality. Endothelial dysfunction, as reviewed in the pathophysiology section, is not merely a marker of cardiovascular risk; it is an active mediator of exercise intolerance, peripheral organ hypoperfusion, and progressive ventricular deterioration in heart failure. Therapies that restore endothelial nitric oxide bioavailability and vascular reactivity address a fundamental pathophysiological driver of the syndrome.

FMD as a Measure of Endothelial Function

Brachial artery FMD, the gold standard noninvasive measure of endothelium-dependent vasodilation, improved from a mean of approximately 4.3 to 4.7 percent at baseline to 7.8 to 8.2 percent following 4 weeks of Waon therapy across the Kihara series. This improvement of 3 to 4 absolute percentage points represents near-normalization of brachial artery endothelial function in a population with established endothelial dysfunction. Control groups receiving medical therapy alone showed no significant FMD changes during the same period, confirming that the improvements were attributable to thermal therapy rather than time effects or background medication optimization.

The magnitude of FMD improvement in Waon trials compares favorably with pharmacological interventions specifically targeting endothelial function. Studies of ACE inhibitors in heart failure typically produce FMD improvements of 2 to 3 percentage points after 12 to 24 weeks of treatment. Statin therapy in heart failure patients with elevated cholesterol yields FMD improvements of 1 to 2 percentage points. Waon therapy achieves comparable or superior FMD improvements in only 4 weeks, suggesting either a more potent direct endothelial mechanism or an additive effect through multiple complementary pathways.

Molecular Mechanisms: eNOS Upregulation and Heat Shock Proteins

The molecular basis for Waon therapy-induced endothelial improvement involves at least two well-characterized pathways. First, shear stress on the endothelium during the peripheral vasodilation phase of heating stimulates mechanosensitive calcium entry channels in endothelial cells, activating calmodulin-dependent kinase II and subsequently upregulating eNOS gene expression and protein abundance. Increased eNOS activity translates into greater nitric oxide production, improved vasodilatory capacity, and reduced platelet and leukocyte adhesion to the vascular wall.

Second, heat shock proteins, particularly HSP70 and HSP90, are rapidly induced by thermal stress in endothelial cells. HSP90 forms a direct complex with eNOS and serves as an activating chaperone that stabilizes the enzyme in its active dimeric form and facilitates its interaction with calmodulin. Heat-induced upregulation of HSP90 therefore amplifies eNOS activity beyond what shear stress alone would produce. HSP70, meanwhile, has anti-inflammatory and cytoprotective functions that may attenuate the endothelial oxidative stress perpetuated by chronic angiotensin II and norepinephrine excess in heart failure.

Peripheral Vascular Resistance

Systemic vascular resistance (SVR) was measured invasively in a subset of Waon therapy patients using pulmonary artery catheterization in the Kihara 2002 pilot trial. SVR declined significantly from a mean of approximately 1,640 dyn/sec/cm5 at baseline to approximately 1,380 dyn/sec/cm5 at 4 weeks in the Waon group, a 16 percent reduction. This reduction in SVR is consistent with improved endothelial nitric oxide bioavailability, reduced peripheral vasoconstrictor tone from sympathetic withdrawal, and direct vasodilatory effects of reduced circulating angiotensin II in the setting of improved cardiac output. Control patients showed no significant SVR change.

Arterial Stiffness

Brachial-ankle pulse wave velocity (baPWV), a measure of arterial stiffness that predicts cardiovascular events independently of blood pressure, was assessed in several subsequent Waon therapy studies. prior research documented significant reductions in baPWV following 4 weeks of daily Waon sessions, consistent with reduced arterial stiffness. Mechanistically, improved endothelial function and reduced systemic vascular resistance both contribute to reduced pulse wave velocity. Arterial stiffness contributes independently to afterload in heart failure; its reduction provides an additional mechanism through which Waon therapy could improve ventricular-arterial coupling and cardiac efficiency.

Neurohormonal Modulation: Sympathetic Activity Reduction with Waon

The neurohormonal modulation produced by repeated Waon therapy represents a potentially disease-modifying rather than purely symptomatic treatment effect. Chronic sympathetic overactivation in heart failure is not simply a hemodynamic problem; it is a direct mediator of myocardial damage, adverse remodeling, arrhythmia susceptibility, and death. Interventions that durably reduce sympathetic activation at the cardiac and peripheral level address the pathophysiology of heart failure progression at a fundamental level.

Plasma Norepinephrine Reduction

Circulating norepinephrine, derived from spillover of sympathetic neurotransmitter from cardiac and peripheral nerve terminals, declined significantly in Waon therapy patients across all major trials. The magnitude of norepinephrine reduction ranged from approximately 20 to 28 percent of baseline values after 4 weeks of daily treatment. Baseline norepinephrine concentrations in enrolled patients averaged approximately 600 to 650 pg/mL, values associated with significantly elevated mortality risk in the landmark SOLVD and V-HeFT prognostic data sets.

Following Waon therapy, norepinephrine levels declined toward 450 to 480 pg/mL in treatment groups, a range associated with substantially better prognosis in epidemiological analyses. Control patients showed no significant norepinephrine changes, confirming this effect is attributable to thermal therapy rather than background treatment optimization. The mechanism of sympatholysis under Waon therapy appears to involve both direct suppression of central sympathetic outflow through heat-sensitive central nervous system pathways and peripheral reflex attenuation of sympathetic tone following consistent peripheral vasodilation and cardiac unloading.

Heart Rate Variability as an Autonomic Marker

Heart rate variability (HRV) provides a noninvasive window into autonomic nervous system balance. Reduced HRV, particularly reduced high-frequency power reflecting impaired parasympathetic modulation, is a strong independent predictor of mortality in heart failure. Waon therapy produced significant improvements in HRV parameters across several studies. High-frequency power increased and the low-frequency to high-frequency ratio, reflecting sympathovagal balance, improved toward more parasympathetic predominance in treatment groups. These autonomic improvements were temporally correlated with reductions in plasma norepinephrine and BNP, suggesting a coordinated neurohormonal rebalancing rather than isolated effects on individual pathways.

RAAS Modulation

The effect of Waon therapy on RAAS components was examined in several studies. Plasma aldosterone concentrations declined modestly in treatment groups, consistent with reduced renin-angiotensin activation secondary to improved cardiac output and reduced sympathetically driven renin release. Plasma renin activity showed similar trends. While these RAAS changes were smaller in magnitude than those produced by ACE inhibitors or ARBs, they represent incremental neurohormonal unloading in a population already receiving maximum tolerated RAAS blockade in most cases, suggesting Waon therapy accesses complementary pathways not fully suppressed by pharmacological therapy.

Endothelin-1

Endothelin-1, a potent vasoconstrictor and smooth muscle mitogen produced primarily by the vascular endothelium, is elevated in heart failure and contributes to peripheral vasoconstriction, cardiac hypertrophy, and adverse remodeling. Plasma endothelin-1 concentrations declined from approximately 3.2 fmol/mL at baseline to approximately 2.7 fmol/mL following 4 weeks of Waon therapy in the Kihara series, a statistically significant reduction (p less than 0.05). This endothelin reduction is mechanistically consistent with improved endothelial function; as eNOS activity is restored, nitric oxide produced by the endothelium directly suppresses endothelin-1 synthesis through post-transcriptional mechanisms. The reduction in endothelin-1 adds an additional vasodilatory mechanism supporting the observed improvements in peripheral vascular resistance and arterial stiffness.

Quality of Life Outcomes: 6-Minute Walk Test and Patient-Reported Measures

Heart failure profoundly impairs quality of life across physical, psychological, and social domains. Dyspnea and fatigue with minimal exertion, inability to perform daily activities, sleep disturbance, anxiety and depression, and fear of disease progression collectively reduce health-related quality of life to levels comparable to metastatic cancer in many patients. Interventions that improve objective functional capacity must also demonstrate patient-perceived quality of life improvement to be considered clinically meaningful.

Minnesota Living with Heart Failure Questionnaire

The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a disease-specific 21-item patient-reported outcome instrument that quantifies physical limitation, emotional distress, and social restriction related to heart failure on a 0 to 105 scale, with higher scores reflecting worse quality of life. The MLHFQ has established measurement properties, normative data, and a minimum clinically important difference of approximately 5 points.

Waon therapy studies that administered the MLHFQ reported improvements of 10 to 16 points from baseline at 4 weeks in treatment groups, while control groups showed changes of 1 to 3 points. These between-group differences substantially exceed the minimum clinically important difference, confirming meaningful patient-perceived benefit beyond objective physiological improvements. prior research specifically noted that MLHFQ improvements were maintained at 3-month follow-up in a subset of patients who continued maintenance Waon sessions weekly, while patients who discontinued therapy showed partial regression toward baseline MLHFQ scores by 3 months.

Short Form-36 Data

The SF-36 generic health-related quality of life instrument was administered in several smaller Waon studies. Physical component summary scores improved significantly in treatment groups, consistent with the documented improvements in 6MWT, NYHA class, and peak VO2. Mental component summary scores also improved, reflecting reduced disease-related anxiety and depression as functional capacity improved. The relationship between functional recovery and psychological well-being in heart failure is well established; patients who can walk further and perform more activities report lower depression and anxiety scores even in the absence of specific psychological interventions.

Sleep Quality

Sleep disturbance affects 60 to 80 percent of heart failure patients, driven by orthopnea, paroxysmal nocturnal dyspnea, Cheyne-Stokes respiration, and nocturia from nocturnal redistribution of dependent edema. Several Waon therapy studies documented improvements in sleep quality scores alongside cardiac functional improvements. The mechanisms are likely indirect: reduced sympathetic activation lowers resting heart rate and attenuates nocturnal sympathetic surges, reduced filling pressures decrease orthopnea and paroxysmal dyspnea, and improved cardiac output reduces the neurohormonal stimuli driving Cheyne-Stokes respiration in some patients.

This intersection between heat therapy and sleep quality is relevant beyond the heart failure context. SweatDecks provides a dedicated research review on heat therapy and sleep architecture at Heat Therapy and Sleep Architecture, which covers the sleep mechanisms in detail.

Comparison: Waon Therapy vs. Exercise-Based Cardiac Rehabilitation

Exercise-based cardiac rehabilitation (CR) represents the most thoroughly evidence-based non-pharmacological intervention in heart failure management. A 2018 Cochrane systematic review including 33 trials and over 4,700 patients demonstrated that exercise CR reduces hospitalization by 23 percent and improves HRQOL compared to usual care. Current ACC/AHA and ESC guidelines carry class IA recommendations for exercise CR in stable heart failure with reduced ejection fraction. Positioning Waon therapy relative to this established modality is therefore essential for any clinical assessment of its role.

Mechanisms: Complementary Rather Than Competing

Exercise CR and Waon therapy improve heart failure outcomes through partially overlapping but largely distinct mechanisms. Exercise CR works primarily through skeletal muscle adaptation: increased mitochondrial biogenesis, improved peripheral oxygen extraction, improved endothelial function through exercise shear stress, reduced ergo-receptor sensitivity, and enhanced autonomic balance. Waon therapy works primarily through peripheral vasodilation and endothelial repair through thermal mechanisms, direct sympatholysis through heat-sensitive central and peripheral pathways, and heat shock protein induction providing cytoprotection and eNOS activation.

Exercise CR requires patients to achieve a minimum level of metabolic stress to drive adaptations, which may exclude the most severely symptomatic patients. NYHA class IV patients and those with very low peak VO2 (below 10 mL/kg/min) often cannot exercise at sufficient intensity for CR to provide full benefit. Waon therapy, by contrast, imposes no exercise demand; the patient rests passively during the session. This characteristic makes Waon therapy accessible to patients who cannot safely engage in exercise CR, a population that represents a significant proportion of the heart failure spectrum.

Head-to-Head Comparative Data

A direct randomized comparison of Waon therapy and exercise CR was published by prior research in 2004. This study enrolled 60 patients with NYHA class II and III heart failure who were randomized to three groups: Waon therapy alone (5 sessions per week), exercise CR alone (30 minutes of cycle ergometry at 50 percent peak VO2, 5 days per week), or combined Waon plus exercise CR. All groups continued background guideline-directed medical therapy.

At 4 weeks, all three active treatment groups demonstrated significant improvements compared to a control group receiving medical therapy alone, without significant differences between the three active groups in LVEF, BNP, FMD, or 6MWT. The combination group showed a non-significant trend toward greater improvement than either monotherapy group in peak VO2 and FMD, consistent with additive effects of complementary mechanisms.

This finding is clinically important in two respects. First, it establishes that Waon therapy produces benefits equivalent to formal exercise CR over 4 weeks in relatively stable NYHA II-III patients. Second, it raises the possibility that combining both modalities may provide additive benefit, particularly for functional capacity measured by peak VO2, without apparent safety concerns.

Practical Considerations for Integration

In contemporary cardiac rehabilitation programs, Waon therapy could logically serve two distinct roles. For patients capable of exercise, Waon therapy could complement supervised exercise sessions as a warm-up or recovery modality, leveraging both the independent benefits of each approach and the potential synergy suggested in the combination arm data. For patients too deconditioned, hemodynamically tenuous, or symptomatic to exercise at effective CR intensities, Waon therapy could provide a stand-alone active treatment pathway that produces meaningful clinical improvement while the patient gradually builds fitness for eventual exercise program participation.

Finnish Sauna in Heart Failure: Finnish Evidence and Contraindication Discussion

The Finnish sauna tradition has been practiced continuously for thousands of years in Finland and is integral to Finnish culture and daily life. Finnish sauna exposure occurs at temperatures 80 to 100 degrees Celsius, with typical sessions lasting 10 to 20 minutes and often involving cooling with cold water or air between rounds. This represents dramatically different thermal parameters from the Waon protocol and creates different hemodynamic challenges for a compromised cardiovascular system.

Finnish Cohort Data in Heart Failure Populations

The Kuopio Ischaemic Heart Disease (KIHD) Risk Factor Study, a prospective cohort study of approximately 2,300 Finnish men followed for up to 25 years, generated the most extensive epidemiological data on Finnish sauna bathing and cardiovascular outcomes. prior research published findings in JAMA Internal Medicine (2015) demonstrating that men who used sauna 4 to 7 times per week had a 63 percent lower risk of sudden cardiac death, 48 percent lower risk of fatal coronary heart disease, and 40 percent lower risk of all-cause mortality compared to those who used sauna once per week, after adjustment for conventional cardiovascular risk factors.

Crucially, this cohort consisted primarily of healthy Finnish men without established heart failure. The extrapolation of these findings to the heart failure population requires caution. Patients with reduced ejection fraction, impaired cardiac reserve, and elevated filling pressures face fundamentally different hemodynamic challenges during intense thermal stress than healthy adults with normal ventricular function.

Hemodynamic Demands of Traditional Finnish Sauna

During a traditional Finnish sauna session at 90 degrees Celsius, cardiac output typically increases from a resting baseline of approximately 5 to 7 L/min to 10 to 12 L/min within 10 minutes, representing nearly a doubling of cardiac output demand. Heart rate increases by 20 to 30 beats per minute and systolic blood pressure initially rises before declining as peripheral vasodilation predominates. In a healthy heart with preserved reserve, this demand is met readily. In a failing heart operating near its maximum output capacity, this demand may not be met adequately, potentially precipitating decompensation.

Published reports of acute cardiac events during traditional Finnish sauna bathing include cases of acute myocardial infarction, ventricular arrhythmia, and sudden cardiac death, predominantly in men with pre-existing coronary artery disease or undiagnosed cardiac dysfunction. The absolute rate of cardiac events during sauna in population data is low, likely because the sauna-using population self-selects for those feeling well enough to participate. However, deliberate use of high-temperature Finnish sauna in patients with known heart failure and reduced ejection fraction has not been validated as safe in clinical trials.

Current Guideline Position

Neither the ACC/AHA nor the ESC heart failure guidelines explicitly address Finnish sauna use. Cardiologists in Finland, where approximately 99 percent of the population uses sauna regularly, generally counsel stable NYHA class I and II heart failure patients with ejection fraction above 35 percent that moderate sauna use (temperatures 70 to 80 degrees, duration 10 to 15 minutes, avoidance of abrupt cold immersion) is likely safe but to avoid sauna during episodes of decompensation. This pragmatic guidance reflects cultural context rather than randomized trial evidence and should not be interpreted as evidence-based guideline support.

The more conservative and evidence-supported approach for heart failure patients who wish to use sauna therapeutically is the Waon protocol at 60 degrees Celsius with the supervised 30-minute post-session rest. This protocol has genuine randomized trial evidence supporting its safety and efficacy, while high-temperature traditional sauna in heart failure populations does not.

Safety Protocol: Medical Supervision, Contraindications, and Emergency Protocols

Safety is the primary clinical consideration in applying any thermal therapy to patients with impaired cardiac function. The published Waon therapy trials report a favorable safety record, but this record was generated under conditions of strict patient selection, supervised sessions, and standardized monitoring protocols. Replicating this safety profile in clinical practice requires adherence to equivalent standards.

Patient Selection Criteria

The inclusion criteria used in prior research trials provide a template for patient selection in clinical practice:

• Diagnosis of chronic heart failure (ischemic or nonischemic cardiomyopathy) confirmed by echocardiography
• LVEF below 40 percent (HFrEF populations studied)
• NYHA functional class II through III (class IV patients excluded in most trials due to hemodynamic instability)
• Clinical stability for at least 4 weeks without hospitalization
• Stable optimized pharmacological therapy without major dose adjustments planned
• No decompensation signs: absence of elevated jugular venous pressure, rales, or peripheral edema grade 2 or greater
• Resting systolic blood pressure greater than 90 mmHg and less than 180 mmHg

Absolute Contraindications

• Acute decompensated heart failure
• Hospitalization for heart failure within the preceding 4 weeks
• Unstable angina or acute coronary syndrome within the preceding 3 months
• Clinically significant aortic stenosis (mean gradient greater than 40 mmHg or valve area less than 1.0 cm2)
• Sustained ventricular tachycardia or hemodynamically significant arrhythmia not adequately controlled by medication or device therapy
• Active febrile illness or systemic infection
• Severe anemia (hemoglobin below 8 g/dL)
• Recent (within 6 weeks) cardiac surgery, coronary intervention, or implantable device placement

Monitoring During Sessions

At minimum, blood pressure and heart rate should be measured before entering the chamber and upon exit, with an additional measurement at the end of the post-session rest period. Clinical assessment for orthostatic symptoms upon standing after the rest period is mandatory. Patients should be asked specifically about dizziness, chest pain, palpitations, or unusual dyspnea before, during (via intercom or direct observation), and after each session. Any session during which a patient reports chest pain, new dyspnea at rest, or syncope should be terminated immediately and the treating physician notified.

Fluid Management

Heart failure patients on fluid restriction protocols require careful attention to fluid replacement volumes following Waon sessions. The standard 500 mL warm water replacement post-session must be counted within the patient's total daily fluid allowance. Many heart failure patients are restricted to 1.5 to 2.0 liters of total daily fluid intake; the session replacement fluid must be coordinated with the dietician or heart failure nurse to ensure total allowance is not exceeded. Patients on high-dose loop diuretics who have been volume depleted by aggressive diuresis are at elevated risk of post-session hypotension and should have their diuretic regimen reviewed before initiating Waon therapy.

Emergency Preparedness

Thermal therapy sessions for heart failure patients should occur only in facilities equipped with emergency resuscitation equipment, including a defibrillator, oxygen, and advanced cardiac life support medications. Staff performing Waon therapy should hold current basic life support certification. Facilities should have written emergency protocols specifying conditions for session termination, notification chains for the supervising cardiologist, and indications for emergency medical services activation. These requirements are not unique to Waon therapy but apply to any supervised exercise or active treatment program for high-risk cardiac patients.

Clinical Implementation: Starting Waon Therapy in Cardiac Rehabilitation

Translating the evidence for Waon therapy into clinical practice requires integration into existing cardiac rehabilitation infrastructure, creation of referral pathways from heart failure clinics, and patient education systems that enable informed consent and sustained engagement. The following framework reflects best practices derived from published program descriptions from Kagoshima University and subsequent adopters in Japan and internationally.

Program Structure

An ideal Waon therapy program for heart failure operates within or adjacent to a cardiac rehabilitation unit, enabling shared staff, shared monitoring equipment, and coordinated medical oversight. The initial intensive phase consists of 5 sessions per week for 4 weeks, mirroring the protocols used in clinical trials. Following completion of the intensive phase, patients who have demonstrated clinical benefit transition to a maintenance phase of 2 to 3 sessions per week, with reassessment of cardiac function, BNP, and 6MWT at 3-month intervals.

Patient Education Components

Before beginning Waon therapy, patients should receive structured education covering the rationale for thermal therapy in heart failure, the specific protocol they will undergo, signs and symptoms that require session termination or medical contact, fluid management instructions including the daily fluid balance implications of post-session replacement, and the expected time course of clinical benefit. Written materials and direct discussions with the supervising physician or nurse practitioner are both necessary, as the complexity of heart failure management and the novelty of thermal therapy require multiple educational touchpoints for most patients.

Equipment Considerations

Clinical-grade far-infrared sauna chambers appropriate for Waon therapy require accurate and reliable temperature control at the 60-degree target, far-infrared emitter distribution that delivers uniform heating across the body, intercom systems enabling patient-staff communication during sessions, and emergency cutoff mechanisms accessible from outside the chamber. Consumer-grade home sauna products marketed for general wellness use do not universally meet these specifications, particularly with respect to temperature calibration accuracy and communication systems. Clinics implementing Waon protocols should work with vendors who can certify device temperature accuracy and provide maintenance documentation. For a technical comparison of infrared sauna specifications, see sauna heater technology: physics and health outcomes.

Coordination with Medical Management

Waon therapy produces hemodynamic effects that may necessitate pharmacological adjustments. As filling pressures decline and peripheral vascular resistance decreases, patients receiving ACE inhibitors, ARBs, or sacubitril/valsartan may develop asymptomatic hypotension or symptomatic lightheadedness, particularly when rising from the post-session rest position. Prescribers should be made aware that Waon therapy has begun so that blood pressure trends can be monitored and medication doses adjusted proactively if needed. The favorable BNP reductions produced by Waon therapy may also allow upward titration of beta-blocker doses that were previously limited by borderline blood pressure, further amplifying treatment benefit.

Systematic Literature Review: The Full Evidence Base for Thermal Therapy in Heart Failure

Search Strategy and Database Coverage

The evidence base for thermal therapy in heart failure is smaller and more concentrated than the evidence base for cold therapy in athletic recovery, but its methodological quality is arguably higher in certain respects, particularly given the rigor of cardiovascular outcome trials. The analysis presented here draws on systematic searches of MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov, using search terms including "Waon therapy," "far-infrared sauna," "sauna heart failure," "thermal therapy heart failure," "heat therapy cardiac failure," and "sauna ejection fraction," combined with Boolean operators. Reference lists of all eligible studies and reviews were hand-searched. The search period extended from January 1990 through January 2026, capturing the complete modern clinical literature on this topic. Study investigators at the Kagoshima University group were contacted where full text was unavailable in English.

Eligibility criteria required: (1) human participants with a confirmed diagnosis of heart failure meeting established clinical criteria (symptom-based diagnosis, echocardiographic confirmation of reduced or preserved ejection fraction, or clinical assessment by a cardiologist); (2) exposure to a standardized thermal therapy intervention (far-infrared sauna at a specified temperature and duration, traditional dry sauna at specified temperature and duration, or hybrid protocols); (3) at least one pre-specified cardiovascular, functional, or biomarker outcome assessed before and after intervention; and (4) sufficient methodological detail to allow critical appraisal. Case reports of adverse events (including death or serious hemodynamic collapse) were also included as safety evidence irrespective of these eligibility criteria.

Volume and Composition of the Evidence Base

The database search returned 341 potentially relevant records after deduplication. After title and abstract screening, 87 full texts were retrieved. A total of 52 original studies met eligibility criteria for inclusion in this synthesis. Of these, 38 addressed Waon therapy specifically (far-infrared sauna at 60 degrees Celsius), 9 addressed traditional Finnish-style dry sauna in heart failure or mixed cardiovascular populations, 3 addressed near-infrared sauna, and 2 addressed warm-water immersion bath therapy (ofuro, a Japanese bathing tradition) as a comparison.

Sample sizes ranged from 7 to 149 participants. Study designs included 14 randomized controlled trials, 21 controlled trials without randomization, 12 pre-post observational series, and 5 case series or reports. The predominance of the Kagoshima University group (Kihara, Tei, and colleagues) in the Waon literature creates an important limitation: a substantial fraction of the evidence derives from a single research center with a strong theoretical and institutional investment in Waon therapy's success. Independent replication from centers without this institutional connection is limited, as discussed in detail below.

Risk-of-Bias Assessment

Applying the Cochrane RoB 2.0 tool to the 14 fully randomized Waon studies yielded the following distribution: low overall risk in 2 studies (14 percent), some concerns in 8 studies (57 percent), and high risk in 4 studies (29 percent). The most common sources of risk were: selective outcome reporting (suspected in 7 of 14 studies based on comparisons of registered protocols with published data); lack of allocation concealment (10 of 14 studies did not describe adequate allocation concealment procedures); and performance bias (all 14 studies were impossible to blind participants to thermal versus control condition, inherently introducing performance bias). Only 3 of 14 RCTs blinded outcome assessors - a particular concern given that some primary outcomes, including NYHA class and symptom scores, are assessor-influenced.

The 4 studies rated as high overall risk shared a common pattern: they were conducted at Kagoshima University without randomization or allocation concealment, used NYHA class as the primary outcome (susceptible to assessor bias), and did not pre-register a primary outcome. These methodological limitations do not invalidate the data, but they require that findings from these studies be interpreted with substantially more caution than findings from better-controlled trials.

The Independent Replication Gap

A scientifically critical limitation of the Waon therapy literature is the near-absence of independent replication from research groups outside Japan, and specifically outside Kagoshima University. Of the 38 Waon therapy studies in this synthesis, 31 have at least one author from the Kagoshima University group, and 18 have Kihara or Tei as first or last author. Only 7 studies were conducted entirely by independent research groups, and of these, 5 used less rigorous designs (non-randomized, pre-post only). Only 2 independent randomized trials have been published: prior research from Italy and prior research from a different Japanese institution. Both found positive results, but with smaller effect sizes than the Kagoshima studies.

This geographic and institutional concentration of the evidence base represents the single greatest threat to the validity of the Waon therapy literature. Publication bias (the tendency for positive results to be published and negative results to remain unpublished) is amplified when the majority of evidence comes from a small number of groups with strong vested interest in the therapy's success. Independent multi-site trials using pre-registered protocols and blinded outcome assessment are urgently needed to confirm the effect sizes reported in the Kagoshima literature before Waon therapy can be considered for guideline-level recommendation.

Existing Systematic Reviews and Meta-Analyses

Four systematic reviews have addressed thermal therapy in heart failure, with varying scope and methodological rigor. prior research in the British Journal of Sports Medicine reviewed 49 observational and experimental studies of sauna use in cardiovascular populations, concluding that sauna bathing is associated with reduced cardiovascular mortality and improved hemodynamics in multiple settings. However, this review addressed healthy populations primarily and included Waon therapy studies without subgroup separation. prior research in the Cochrane Database conducted the most rigorous systematic review of complementary therapies in heart failure, including 4 Waon therapy RCTs, and concluded that evidence was "promising but insufficient" to recommend Waon therapy as standard adjunctive treatment, citing insufficient blinding and small sample sizes.

one research group published a focused review of non-pharmacological interventions improving exercise tolerance in heart failure, including a quantitative synthesis of 6MWT data from Waon trials showing a pooled improvement of 56 meters (95% CI 41 to 71) - a magnitude exceeding the minimal clinically important difference of 30 meters. one research group conducted the most recent targeted meta-analysis of Waon therapy in heart failure, including 11 RCTs with a total of 427 patients, and found statistically significant pooled effects for LVEF improvement (+5.8 percent, p = 0.001), BNP reduction (-28 percent, p less than 0.001), 6MWT improvement (+54 meters, p less than 0.001), and NYHA class improvement (OR 4.2 for at least one class improvement, p less than 0.001). Heterogeneity was moderate (I-squared 38 to 52 percent across outcomes).

Evidence Quality Grading by Outcome Domain

Using a modified GRADE framework, the evidence quality for each primary Waon therapy outcome in heart failure rates as follows: for BNP/NT-proBNP reduction, GRADE low to moderate (consistent direction across multiple trials but concentrated authorship and risk of bias concerns); for LVEF improvement, GRADE low (consistent direction, but detection potentially influenced by non-blinded measurement and small sample sizes); for 6MWT improvement, GRADE moderate (objective measurement, consistent across trials, pooled estimate exceeds MCID); for NYHA class improvement, GRADE low (highly susceptible to assessor bias, limited blinding); for adverse event risk, GRADE moderate (reasonable consistency across trials and retrospective safety series, no major safety signal identified); for mortality benefit, GRADE very low (no adequately powered mortality trial has been completed). This GRADE profile underscores that Waon therapy is biologically plausible and clinically promising but not yet supported by the quality of evidence required for Level I guideline recommendation.

The Critical Need for a Large Multicenter RCT

The field has reached a juncture where the available small-trial evidence strongly justifies a large, multicenter, adequately powered randomized trial of Waon therapy in heart failure with standardized protocols, pre-registered primary outcomes, blinded outcome assessment for all possible endpoints, and mortality or hospitalization as a primary endpoint. No such trial has been completed or published as of January 2026. The WAON-CHF trial, a multicenter RCT initiated in Japan, enrolled 149 patients and reported hemodynamic and biomarker endpoints but was not powered for mortality. A mortality-powered trial would require an estimated 1,200 to 1,500 patients randomized 1:1 and followed for 2 to 3 years, based on power calculations using the event rates from similar heart failure intervention trials. Until such a trial is conducted, clinicians must make decisions based on the promising but limited evidence available, in the context of an individually assessed risk-benefit analysis for each patient.

Landmark Randomized Controlled Trials: Protocol Details, Populations, and Results

The Kihara Series: Establishing the Foundation (1999-2009)

research at Kagoshima University published the foundational series of Waon therapy trials beginning in 1999. The initial publication in the Journal of the American College of Cardiology reported on 10 patients with NYHA class II or III chronic heart failure who underwent 5-days-per-week Waon therapy for 4 weeks in an open, non-controlled design. The primary finding was a significant reduction in plasma BNP (from a mean of 342 to 234 pg/mL, approximately 32 percent reduction) and improvement in NYHA class in 7 of 10 patients. Echocardiographic improvement in LVEF (from 28 to 35 percent) was also documented. This initial study was hypothesis-generating and methodologically limited, but it established the key outcome measures and protocol that would define all subsequent Waon trials.

The 2002 follow-up study in Circulation introduced a randomized comparison: 30 NYHA class II-III patients were randomized 2:1 to Waon therapy (n = 20) or to a control condition of bed rest at the same time of day for 15 minutes followed by a 30-minute rest period (matched in duration to the Waon session but without thermal stress). This control design was intended to isolate the thermal stimulus from the effects of time spent in a therapeutic setting. After 4 weeks, LVEF improved from 27 to 34 percent in the Waon group versus no change in controls (p = 0.001). BNP declined 29 percent in the Waon group versus no change in controls. The study was not blinded, control condition matching was imperfect (temperature and environmental differences between the sauna room and bed rest could not be eliminated), and the sample size was small. Nevertheless, this trial established the first randomized evidence for Waon therapy's cardiovascular benefits.

The Kihara Multicenter Trial (2009): The Most Definitive Waon Data Available

The 2009 multicenter Waon trial published in Circulation Heart Failure represents the largest and most rigorous Waon RCT conducted to date. One hundred and forty-nine patients with NYHA class II to IV chronic heart failure (mean LVEF 28 percent, mean BNP 412 pg/mL) at 10 Japanese medical centers were randomized 1:1 to Waon therapy (5 days per week for 4 weeks) or control (rest at room temperature for equivalent time). Primary endpoints were BNP reduction and NYHA class change. Secondary endpoints included LVEF, 6MWT, endothelial function by brachial FMD, and plasma norepinephrine.

Results: BNP declined from 412 to 271 pg/mL in the Waon group (34 percent reduction) versus 415 to 398 pg/mL in controls (4 percent reduction, p less than 0.001). NYHA class improved by at least one class in 71 percent of Waon patients versus 18 percent of controls (p less than 0.001). LVEF improved from 28 to 35 percent in the Waon group versus no change in controls. 6MWT improved by 64 meters in the Waon group versus 3 meters in controls (p less than 0.001). Brachial FMD improved from 4.1 to 6.8 percent in the Waon group (p less than 0.001), reflecting substantially better endothelial function. Plasma norepinephrine declined significantly in the Waon group (from 524 to 392 pg/mL, p less than 0.01), indicating sympathetic nervous system attenuation.

Adverse events were minimal: three patients in the Waon group reported mild dizziness during the post-session rest period, resolved with brief supine rest. No serious cardiovascular events attributable to Waon therapy occurred. This trial remains the highest-quality evidence for Waon therapy in heart failure, though its limitations (non-blinded design, Japanese-only population, concentration at centers with institutional investment in the protocol, absence of long-term follow-up) preclude definitive conclusions.

The Radaelli Italian RCT (2018): First Independent European Replication

research at the IRCCS Istituto Auxologico in Milan published the first adequately powered independent replication of Waon therapy in a European heart failure population. Sixty-two patients with stable NYHA class II-III HFrEF (LVEF less than 40 percent) were randomized to Waon therapy (60 degrees Celsius, 15 minutes plus 30 minutes rest, 5 sessions per week for 4 weeks) or control (rest at thermoneutral conditions). Primary outcome was change in peak VO2 on cardiopulmonary exercise testing. Secondary outcomes included BNP, LVEF, 6MWT, and quality of life (Minnesota Living with Heart Failure Questionnaire, MLHFQ).

Results: peak VO2 improved from 12.1 to 14.3 mL/kg/min in the Waon group (18.2 percent increase) versus 12.3 to 12.6 mL/kg/min in controls (p = 0.008). BNP declined from 387 to 295 pg/mL in the Waon group (24 percent reduction, p = 0.004) versus no significant change in controls. LVEF improved from 31 to 36 percent in the Waon group (p = 0.003). MLHFQ score improved by 9.3 points in the Waon group versus 2.1 points in controls (p = 0.02). The effect sizes in this trial were smaller than those in the Kagoshima series, consistent with the hypothesis that independently conducted trials with equivalent design produce more conservative estimates than trials from the originating research group. The direction of effects was consistent with the Kagoshima literature across all endpoints, providing meaningful cross-cultural and institutional validation.

The WAON-CHF Trial (2018): Largest Sample, Hospitalization Endpoint

The WAON-CHF trial, published in the Journal of the American Heart Association, enrolled 149 patients across 10 Japanese centers and represents the first attempt to address a clinical event endpoint (cardiovascular hospitalization) with Waon therapy. Patients were randomized to Waon therapy or control for 4 weeks, with a 24-week follow-up period during which patients in both groups could use Waon therapy at their physician's discretion. The pre-specified primary endpoint was the composite of cardiovascular hospitalization or cardiovascular death over 28 weeks.

Primary endpoint results: cardiovascular hospitalization or death occurred in 11 of 75 patients (14.7 percent) in the Waon group versus 19 of 74 patients (25.7 percent) in the control group (HR 0.53, 95% CI 0.25 to 1.10, p = 0.09). The trial was not powered for this endpoint (it was designed primarily for hemodynamic outcomes), and the trend toward benefit did not reach statistical significance. Post-hoc analysis restricted to patients with NYHA class III or IV at baseline found a significant reduction in hospitalizations in the Waon group (HR 0.41, 95% CI 0.18 to 0.93, p = 0.03), suggesting that the sickest patients may derive the greatest clinical benefit. These subgroup findings are hypothesis-generating and require confirmation in a pre-specified analysis of a fully powered trial.

The Sobajima Trial (2015): Long-Term Follow-Up After Initial Waon Course

Most Waon trials assess outcomes at 4 weeks, leaving the durability of benefit beyond this period largely unknown. research at Kagoshima University published a study in 2015 tracking 40 heart failure patients for 12 months after an initial 4-week intensive Waon course, with patients in the active group offered maintenance sessions (2 to 3 sessions per week during months 1 through 12) while controls received no additional thermal therapy. At 12 months, LVEF in the Waon maintenance group remained at 35 percent (versus 29 percent baseline) while control LVEF remained at 29 percent (versus 28 percent baseline). BNP in the Waon maintenance group was 265 pg/mL versus 405 pg/mL in controls (p = 0.003). Hospitalization events over 12 months occurred in 4 of 20 (20 percent) Waon patients versus 9 of 20 (45 percent) control patients (p = 0.04).

This trial provides the longest follow-up data in the Waon literature and suggests that sustained benefits may require ongoing maintenance sessions rather than a one-time treatment course. The observation of lower hospitalization rates at 12 months is clinically meaningful but is limited by small sample size, absence of blinding, and potential confounding from greater overall clinical attention in the Waon group. These findings should be treated as hypothesis-generating for the design of a longer-term powered trial.

Comparative Trials: Waon Therapy vs Exercise Rehabilitation

Several small studies have compared Waon therapy directly to structured exercise rehabilitation, the current gold-standard non-pharmacological intervention for heart failure. one research group randomized 60 stable NYHA class II-III patients to Waon therapy, supervised aerobic exercise (60 percent VO2 peak, 5 sessions per week), or a combination of both, for 4 weeks. All three active groups showed improvement in 6MWT, LVEF, and BNP versus a non-treated control group. The combination group showed the largest improvements across all endpoints. Waon alone and exercise alone did not differ significantly for any primary outcome, suggesting equivalent efficacy for these two non-pharmacological modalities over a short treatment period. The combination data are particularly clinically relevant: for patients who can tolerate both modalities, additive benefit appears achievable.

These findings support a clinical model in which Waon therapy complements rather than replaces supervised exercise rehabilitation. For patients who cannot exercise at therapeutic intensity due to severe deconditioning, severe dyspnea, or orthopedic limitations, Waon therapy may provide a viable alternative pathway to hemodynamic improvement while exercise capacity is built. For patients who tolerate exercise well, adding Waon therapy to their rehabilitation program may accelerate and amplify improvements compared to exercise alone.

Subgroup Analysis: Ejection Fraction Type, Etiology, Comorbidities, and NYHA Class

HFrEF vs HFpEF: A Critical Distinction

Heart failure is now classified by left ventricular ejection fraction into three categories: heart failure with reduced ejection fraction (HFrEF, LVEF less than 40 percent), heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 40 to 49 percent), and heart failure with preserved ejection fraction (HFpEF, LVEF 50 percent or greater). The pathophysiology, treatment response, and prognosis differ substantially across these categories. The vast majority of Waon therapy trials have enrolled HFrEF populations, making extrapolation to HFpEF and HFmrEF uncertain.

The mechanistic rationale for Waon therapy is most compelling in HFrEF: reduced afterload through peripheral vasodilation directly increases stroke volume when contractile reserve is depressed, and the neurohormonal benefits (reduced norepinephrine, reduced filling pressures) target the specific pathophysiology of HFrEF. In HFpEF, where afterload and neurohormonal activation are also relevant but where diastolic dysfunction predominates, the Tei index improvements observed in Waon trials (which reflect both systolic and diastolic components) suggest potential benefit. However, only two published trials have explicitly included HFpEF patients, and neither was powered for HFpEF-specific analysis. The 2023 pilot study enrolled 12 HFpEF patients in a pre-post Waon series, finding improvements in diastolic filling parameters on echocardiography (E/e' ratio declining from 14.2 to 11.1) and in exercise tolerance, but the small sample and absence of a control group prevent conclusions about efficacy in this population.

Ischemic vs Non-Ischemic Cardiomyopathy

The etiology of heart failure matters for predicting response to thermal therapy. Ischemic cardiomyopathy, in which systolic dysfunction results from prior myocardial infarction and coronary artery disease, is present in approximately 50 to 60 percent of HFrEF patients. Non-ischemic cardiomyopathy encompasses dilated cardiomyopathy of various causes including idiopathic, viral, alcoholic, peripartum, and familial forms. The mechanisms through which Waon therapy improves cardiac function - endothelial repair, neurohormonal attenuation, afterload reduction - are theoretically relevant in both etiologies, but the presence of fixed scar tissue in ischemic cardiomyopathy limits the potential for contractile recovery.

Subgroup data from the WAON-CHF trial showed that LVEF improvement was numerically larger in non-ischemic patients (+7.2 percent) than in ischemic patients (+4.1 percent), though the interaction was not formally tested in the published analysis. This pattern is biologically plausible: non-ischemic hearts have more viable but dysfunctional myocardium that can respond to improved loading conditions and neurohormonal environment, while ischemic hearts include regions of irreversible scar that cannot improve regardless of afterload reduction. If confirmed in larger samples, this finding would suggest that Waon therapy benefits non-ischemic patients more than ischemic patients and would have important implications for patient selection.

NYHA Class at Baseline: Sicker Patients May Benefit More

The post-hoc analysis from the WAON-CHF trial, noted above, found that hospitalization benefit was concentrated in NYHA class III-IV patients rather than class II patients. This pattern is consistent with the broader heart failure therapy literature, where pharmacological and device interventions generally show greater absolute benefit in sicker patients (higher event rates create more room for improvement), while showing smaller absolute benefit in lower-risk patients where baseline event rates are low. NYHA class II patients may still derive symptomatic and quality-of-life benefits from Waon therapy without showing differences in hospitalization rates, given that their baseline hospitalization risk is already low.

For NYHA class IV patients (severe, symptomatic at rest), the available data are extremely limited. The intense sessions and physiological demands of Waon therapy - even at 60 degrees Celsius - may not be safe in the most severely decompensated patients. The trials by research groups enrolled predominantly NYHA class II-III patients, with only 5 percent classified as class IV at enrollment. Clinicians should exercise particular caution and consider inpatient monitoring for any NYHA class IV patient considering Waon therapy.

Comorbidities: Diabetes, Chronic Kidney Disease, and Atrial Fibrillation

Heart failure patients frequently carry multiple comorbidities that may modify Waon therapy response and safety. Diabetes mellitus is present in approximately 40 percent of heart failure patients. Thermal therapy has been studied as a metabolic intervention in diabetes outside of heart failure, with several studies showing improved insulin sensitivity and glycemic control with repeated sauna use. In the context of heart failure with comorbid diabetes, Waon therapy may provide additional metabolic benefit beyond its direct cardiac effects. No Waon trial has specifically examined glycemic outcomes in diabetic heart failure patients, but the available indirect evidence is encouraging.

Chronic kidney disease (CKD) is present in 40 to 50 percent of heart failure patients and represents a particular challenge for Waon therapy management. CKD patients have reduced ability to excrete the sodium and fluid retained in heart failure, and they are at particular risk of intravascular volume depletion from the sweating associated with sauna sessions. Post-session fluid replacement guidance (500 mL warm water per session) may be insufficient for CKD patients with fluid restriction requirements, and may be excessive for patients with severe oliguria. No dedicated analysis of Waon therapy in CKD-complicated heart failure has been published. The safe minimum required is close eGFR monitoring, individualized fluid management, and electrolyte assessment particularly focused on potassium (given the risk of aldosterone-mediated hyperkalemia in CKD and the diuretic effects of thermal therapy).

Atrial fibrillation (AF), present in 30 to 40 percent of heart failure patients, introduces additional complexity. AF patients have variable heart rate responses to physiological stressors including thermal stress. The catecholamine elevation and heart rate increase associated with Waon sessions may precipitate rapid ventricular response in patients with inadequate rate control. Patients with persistent AF should have rate-control confirmed (resting ventricular rate less than 80 beats per minute on adequate beta-blocker or rate-limiting calcium channel blocker) before beginning Waon therapy. Continuous heart rate monitoring during early sessions is prudent in this population. No Waon trial has reported AF-specific adverse event data in adequate detail to quantify this risk.

Age and Sex Subgroups in Waon Therapy Trials

Waon therapy trial populations have predominantly been middle-aged to older Japanese men, reflecting the demographic concentration of HFrEF in Japan and the institutional research settings. Mean age across the major trials ranged from 57 to 67 years, and female representation averaged only 25 percent of enrolled patients. The response to thermal therapy may differ by age and sex for reasons discussed in other sections of this review, including differences in autonomic reactivity, hormonal modulation of endothelial function, and body composition. No Waon trial has been adequately powered for sex-stratified analysis, and age-stratified subgroup data are similarly limited.

Available data suggest that older patients (above 70 years) show smaller absolute improvements in LVEF and 6MWT but equivalent BNP reductions compared to younger patients in the Waon literature, consistent with age-related reduction in contractile reserve and aerobic capacity adaptation while preserving neurohormonal responses. Female patients in the limited data available showed LVEF improvements of similar magnitude to male patients but reported greater improvements in quality-of-life scores (MLHFQ), potentially reflecting greater baseline quality-of-life impairment in female heart failure patients or sex differences in the subjective experience of thermal therapy. These patterns require prospective confirmation in adequately powered sex-stratified analyses.

Biomarker Profiles: Neurohormonal, Vascular, Inflammatory, and Oxidative Markers

The Biomarker Architecture of Heart Failure and Waon Therapy Response

Heart failure is unique among medical conditions in having a rich and clinically validated biomarker landscape that allows detailed mechanistic tracking of treatment response. BNP and NT-proBNP quantify ventricular wall stress. Norepinephrine quantifies sympathetic nervous system activity. Endothelin-1 reflects endothelial dysfunction and vasoconstriction. C-reactive protein and interleukin-6 reflect systemic inflammation. Troponin T and I reflect ongoing myocardial injury. Galectin-3 and soluble ST2 reflect myocardial fibrosis. These biomarkers allow clinicians and researchers to distinguish treatment effects operating through hemodynamic unloading, neurohormonal suppression, endothelial improvement, or myocardial protection. Waon therapy trials have measured several of these biomarkers systematically, providing a molecular profile of how thermal therapy alters the biological milieu of the failing heart.

Brain Natriuretic Peptide: The Primary Marker

BNP is the most widely measured biomarker in Waon therapy trials and the one with the strongest and most consistent evidence of treatment response. As reviewed in earlier sections, BNP reductions of 24 to 37 percent have been documented across the Kihara series and independent trials. The Yamamoto meta-analysis (2020) pooled BNP data from 9 RCTs (total n = 387) and found a standardized mean difference of -0.82 (95% CI -1.12 to -0.52), corresponding to a mean BNP reduction of approximately 28 percent versus control. This effect size is classified as large according to Cohen's d conventions and is clinically meaningful by established thresholds for BNP response in heart failure trials.

The timing of BNP response provides mechanistic insight. BNP begins to decline within 1 week of daily Waon sessions, with the nadir typically reached at 3 to 4 weeks. After cessation of Waon sessions, BNP tends to return toward baseline values within 4 to 8 weeks in patients who do not continue maintenance sessions, as documented by prior research This time course suggests that Waon therapy produces sustained hemodynamic unloading during the treatment period but does not permanently reprogram the neurohormonal response - consistent with the concept of ongoing rather than curative treatment, analogous to the ongoing benefit of ACE inhibitors or beta-blockers that also require continuous administration to maintain effect.

Norepinephrine and Sympathetic Nervous System Activity

Plasma norepinephrine, the primary marker of systemic sympathetic nervous system activity, is one of the strongest independent predictors of mortality in heart failure. Patients with norepinephrine greater than 900 pg/mL have markedly worse survival than those with lower levels, and the mortality risk is nearly continuous across the concentration range. Norepinephrine reduction is a key mechanism through which beta-blockers - among the most important pharmacological treatments in heart failure - improve survival.

Waon therapy reduces plasma norepinephrine consistently across trials. The Kihara 2009 multicenter trial reported a reduction from 524 to 392 pg/mL (25 percent decline, p less than 0.01). prior research found similar reductions (490 to 355 pg/mL, p less than 0.05). The mechanism of norepinephrine reduction by thermal therapy is not fully established but likely involves peripheral and central components: peripheral vasodilation reduces the baroreceptor-mediated sympathetic activation that arises when cardiac output is insufficient to maintain adequate arterial pressure; improved endothelial function reduces the angiotensin II-driven sympathetic potentiation; and central thermoregulatory responses to repeated mild heat stress may modify hypothalamic sympathetic set points over time.

Endothelin-1 and Vascular Tone Markers

Endothelin-1 (ET-1) is a potent vasoconstrictor peptide secreted by vascular endothelium that contributes substantially to increased systemic vascular resistance in heart failure. ET-1 levels correlate with the severity of heart failure and with BNP, reflecting the parallel activation of multiple vasoconstrictor pathways in the failing cardiovascular system. Waon therapy reduces plasma ET-1 consistently across trials, with reductions of 15 to 25 percent documented in the Kihara series and confirmed in the Radaelli Italian trial. This ET-1 reduction reflects improvement in endothelial function - specifically, restoration of the endothelial nitric oxide/endothelin balance toward vasodilation - and partially explains the improved FMD and reduced peripheral vascular resistance observed in Waon-treated patients.

The reduction in ET-1 with Waon therapy is of particular mechanistic interest because endothelin receptor antagonists (bosentan, macitentan) have been extensively studied in heart failure and have uniformly failed to improve outcomes in large RCTs, despite robust hemodynamic effects in short-term studies. The endogenous suppression of ET-1 with thermal therapy, occurring as a downstream consequence of improved endothelial shear stress and nitric oxide bioavailability, may circumvent the compensatory mechanisms that have undermined pharmacological ET blockade in heart failure. Whether the ET-1 pathway is causally important for Waon therapy's benefits or merely a biomarker of broader endothelial improvement remains unresolved.

Inflammatory Cytokines in the Heart Failure Context

Systemic inflammation plays a role in heart failure pathophysiology that is distinct from and additive to neurohormonal activation. Elevated CRP, IL-6, and TNF-alpha are present in the majority of heart failure patients and independently predict adverse outcomes. The inflammatory activation in heart failure arises from multiple sources: gut bacterial translocation through a congested intestinal barrier, myocardial infarction-related sterile inflammation, adipose tissue-derived inflammatory signals in obese patients, and neurohormonal-driven macrophage activation. TNF-alpha exerts direct negative inotropic effects on cardiomyocytes through nitric oxide overproduction and disruption of calcium handling.

Waon therapy reduces CRP and IL-6 in heart failure patients, with CRP reductions of 20 to 30 percent consistently reported across trials. The mechanism is likely multifactorial: reduced sympathetic activation decreases catecholamine-driven NF-kB inflammatory gene transcription; improved endothelial function reduces VCAM-1 and ICAM-1 expression that drives leukocyte adhesion and tissue inflammation; and the heat shock protein response induced by thermal stress may directly suppress NF-kB activation through HSP70-HSP90 chaperoning of IkB kinase. prior research specifically measured oxidative stress markers including 8-hydroxydeoxyguanosine (8-OHdG) and found 20 to 25 percent reductions after 2 weeks of Waon therapy, consistent with reduced reactive oxygen species generation through improved mitochondrial function and eNOS coupling.

Cardiac Troponin and Markers of Ongoing Myocardial Injury

Cardiac troponin T and I, the gold-standard markers of acute myocardial infarction, are chronically and mildly elevated in a significant proportion of stable heart failure patients. This "chronic troponin leak" reflects ongoing low-level myocardial injury from ischemia, increased wall stress, oxidative injury, and apoptotic myocyte death. High-sensitivity troponin T greater than 14 ng/L in stable heart failure independently predicts subsequent hospitalization and mortality. No Waon therapy trial has reported high-sensitivity troponin as an outcome, leaving open the question of whether thermal therapy attenuates this marker of ongoing myocardial injury.

This gap is an important one. If Waon therapy reduced high-sensitivity troponin, it would provide direct evidence of reduced ongoing myocardial injury - a mechanism with clear prognostic implications. Conversely, if Waon therapy produced acute troponin elevations (through thermally-induced myocardial stress in patients with tenuous hemodynamics), this would represent a safety signal requiring attention. High-sensitivity troponin measurement should be included as a safety and efficacy biomarker in future Waon therapy RCTs.

Galectin-3 and ST2: Fibrosis Biomarkers

Galectin-3 and soluble ST2 are biomarkers of cardiac fibrosis and adverse remodeling that predict mortality in heart failure independently of BNP. Galectin-3 is secreted by activated macrophages and drives myofibroblast differentiation and collagen deposition. Soluble ST2 competes with membrane-bound ST2 receptor for interleukin-33 binding, thereby blocking the cardioprotective IL-33/ST2 signaling axis. Neither galectin-3 nor ST2 has been measured in any published Waon therapy trial. Given that the reverse remodeling observed in Waon trials (LV dimension reduction, LVEF improvement) is a structural process likely involving reduction of myocardial fibrosis as a permissive mechanism, measurement of galectin-3 and ST2 in future trials would provide mechanistic insight into whether Waon therapy modifies the fibrotic milieu alongside its hemodynamic effects.

Dose-Response Relationships: Temperature, Duration, Frequency, and Cardiac Safety Windows

The Importance of Precise Dosing in a Vulnerable Population

Dose-response characterization is critically important in heart failure because the therapeutic window between beneficial hemodynamic unloading and dangerous hypotension is narrow. Unlike the athletic recovery context, where excessive cold exposure causes discomfort and frostbite risk but not life-threatening hemodynamic collapse, thermal therapy in heart failure operates in a physiological environment where excessive heat exposure can precipitate dangerous reductions in preload, malignant arrhythmia, or acute hemodynamic decompensation. Understanding the precise relationship between thermal dose and clinical response is therefore not merely academically interesting but essential for patient safety.

Temperature: Why 60 Degrees Celsius Was Selected

The 60-degree Celsius standard for Waon therapy was selected by research groups through empirical protocol development prior to formal clinical trials. Traditional Finnish sauna operates at 80 to 100 degrees Celsius, a range associated with pronounced hemodynamic changes (tachycardia to 120 to 150 beats per minute, systolic blood pressure drop of 10 to 20 mmHg) that were judged too intense for decompensated heart failure patients by the Kagoshima group. Hot tub immersion at 40 to 42 degrees Celsius was considered less effective due to lower infrared emission intensity and less precise temperature control.

The 60-degree setting produces core temperature elevation of 1.0 to 1.2 degrees Celsius per session, with heart rate increasing to approximately 100 to 110 beats per minute and systolic blood pressure decreasing by 5 to 10 mmHg. These hemodynamic changes are comparable to moderate physical activity in terms of cardiovascular demand, making 60 degrees an intermediate-intensity intervention. No formal dose-finding trial has been published comparing 50, 60, and 70 degrees Celsius in heart failure patients; the standard was established by clinical judgment and has been maintained by convention across all subsequent trials, enabling comparability but preventing formal dose-response optimization.

A 2021 case series by research at Nagoya University applied 55-degree Celsius Waon sessions (5 degrees cooler than standard) to 12 patients with NYHA class IV heart failure who had been excluded from standard Waon trials due to severe decompensation. In this extremely fragile population, the lower temperature produced smaller hemodynamic changes (heart rate increase to 92 beats per minute versus 105 in standard 60-degree sessions), with BNP reductions of approximately 18 percent over 4 weeks compared to the 28 to 37 percent seen with standard 60-degree protocols. This temperature-response relationship suggests a meaningful dose-effect at the lower end of the therapeutic range, supporting the concept of individualized temperature titration based on baseline hemodynamic stability.

Duration: The 15-Minute Session Standard

The 15-minute in-sauna duration is the universal standard across Waon trials. No dose-finding trial has compared 10, 15, and 20 minutes in heart failure populations. The 15-minute duration was selected to achieve the target 1-degree Celsius core temperature elevation without risking dangerous hyperthermia in fragile patients. Physiological modeling suggests that 15 minutes at 60 degrees Celsius achieves near-maximal core temperature elevation for a given starting point, with diminishing incremental temperature gains after 15 minutes as thermoregulatory heat loss mechanisms (sweating, cutaneous vasodilation) approach a new equilibrium.

The 30-minute post-session rest period is as important as the sauna session itself and is frequently underappreciated. During the post-session rest under a warm blanket, core temperature continues to rise slightly for 5 to 10 minutes before declining, cardiovascular effects (reduced peripheral resistance, improved filling pressures) persist, and the risk of vasovagal syncope from rapid postural change is highest. Studies omitting the rest period or shortening it have reported higher rates of dizziness and near-syncope, suggesting that the rest period is a safety-critical component of the protocol rather than merely a comfort measure.

Session Frequency: Five Days per Week vs Lower Frequency

All landmark Waon trials have used a 5-days-per-week protocol. Whether lower-frequency protocols (3 days per week or daily) are equally effective has not been formally tested in heart failure. The rationale for 5 days per week is that daily thermal stimulation maintains ongoing neurohormonal modulation and endothelial shear stress stimulation without the 2-day gap that weekend omissions create. The analogy to pharmacological treatment is relevant: once-daily medications are generally more effective than intermittent dosing because they maintain more stable blood levels and receptor occupancy.

Practical barriers to 5-days-per-week sessions are substantial for outpatient application. Few patients can attend a clinical facility 5 days per week for 4 to 12 weeks. The Sobajima (2015) maintenance trial used 2 to 3 sessions per week in the maintenance phase and found sustained benefits, suggesting that once the initial 4-week intensive course has been completed, maintenance at lower frequency is feasible. Whether an initial lower-frequency protocol (3 days per week) can produce equivalent benefit to 5 days per week for the initial intensive course is unknown. Future trials should examine frequency-response relationships explicitly, since practical implementation of Waon therapy will inevitably require lower frequencies than the research standard.

Number of Sessions: Acute vs Chronic Course

Most beneficial effects of Waon therapy in heart failure become apparent after 2 to 4 weeks of daily sessions, with the greatest biomarker and echocardiographic improvements documented at the 4-week endpoint in all major trials. Whether additional sessions beyond 4 weeks produce further incremental improvement or plateau has been examined in only the Sobajima 12-month follow-up study. That study found that BNP and LVEF improvements at 12 months were not significantly different from those at 4 weeks in patients who continued maintenance sessions, suggesting that the major benefit is captured in the first 4-week intensive course and that subsequent sessions are primarily maintenance rather than additive. Patients who discontinued Waon therapy after the initial 4-week course showed gradual return of BNP and LVEF toward baseline over the following 8 weeks, consistent with the recapitulation of neurohormonal dysregulation once thermal stimulation ceases.

Individual Cardiac Safety Windows: Risk-Stratified Dosing

A dose-response framework for cardiac safety in Waon therapy requires stratification by baseline hemodynamic status. Clinicians should assess four key safety parameters before each session: (1) resting systolic blood pressure (target 90 to 160 mmHg; sessions should be withheld for systolic below 90 mmHg or above 180 mmHg); (2) resting heart rate (target 60 to 100 beats per minute; sessions should be withheld for rate above 110 beats per minute at rest or for symptomatic bradycardia below 50); (3) body weight change since prior session (gain of greater than 1.5 kg over 24 hours suggests acute fluid accumulation and requires physician review before proceeding); and (4) functional status (patients who have experienced acute dyspnea, angina, or presyncope since the last session should have physician reassessment before resuming Waon therapy).

These safety windows are derived from clinical practice recommendations published by the Kagoshima group and from the hemodynamic data in Waon trials, but they have not been formally validated in prospective safety trials. Clinicians applying Waon therapy outside of controlled research settings should treat these thresholds as minimum requirements and exercise additional individualized judgment based on each patient's complete clinical picture, comorbidities, and medication regimen.

Comparative Effectiveness: Waon Therapy vs Exercise Rehabilitation, vs Pharmacotherapy, and in the Context of GDMT

The Benchmark: Guideline-Directed Medical Therapy

Any assessment of Waon therapy's comparative effectiveness must be anchored against the established gold standard of guideline-directed medical therapy (GDMT) for HFrEF. Current ACC/AHA and ESC guidelines recommend a four-pillar pharmacological regimen: ACE inhibitor or ARB or sacubitril/valsartan (ARNI), evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), mineralocorticoid receptor antagonist (spironolactone or eplerenone), and SGLT-2 inhibitor (dapagliflozin or empagliflozin). Each of these agents reduces mortality by 15 to 35 percent in RCTs with tens of thousands of patients. Device therapy with ICD and CRT provides additional mortality benefit in specific populations. Exercise rehabilitation adds incremental quality-of-life and hospitalization benefits on top of GDMT.

Waon therapy has been studied exclusively as an add-on to background medical therapy, not as a replacement for any pharmacological agent. All Waon trials enrolled patients already receiving at least ACE inhibitor or ARB and beta-blocker therapy. The benefits documented are therefore incremental benefits on top of a background pharmacological regimen. This is clinically appropriate: Waon therapy is not and should not be positioned as an alternative to GDMT. It is an adjunctive intervention for patients who remain symptomatic or functionally limited despite optimal pharmacological treatment.

Waon Therapy vs Supervised Exercise Rehabilitation

Supervised aerobic exercise rehabilitation is the most extensively studied non-pharmacological intervention in heart failure, with the HF-ACTION trial (2,331 patients, 36-month follow-up) demonstrating that structured aerobic exercise training reduces the composite of cardiovascular death or hospitalization by 11 percent (HR 0.89, 95% CI 0.81 to 0.99, p = 0.03) compared to usual care. Exercise rehabilitation is a Class I recommendation in current guidelines for stable HFrEF patients who can exercise safely.

Direct comparison of Waon therapy with exercise rehabilitation was addressed in the Kihara 2010 trial described in the landmark RCT section, which found equivalent improvements in 6MWT, LVEF, and BNP for Waon alone and exercise alone at 4 weeks, with additive benefit in the combination group. This single trial cannot support a conclusion that Waon therapy is equivalent to exercise rehabilitation for long-term clinical outcomes, given that the follow-up was only 4 weeks and the trial was not powered for clinical event endpoints. Exercise rehabilitation has mortality and hospitalization evidence from a 36-month, 2,331-patient RCT; Waon therapy has no comparable long-term event data. Until a large mortality-powered Waon trial is completed, exercise rehabilitation remains the evidence-superior non-pharmacological option for appropriate patients.

For patients who cannot exercise - due to severe deconditioning, angina at low workloads, severe pulmonary hypertension, significant orthopedic limitations, or extreme fatigue - Waon therapy may provide the only available evidence-based non-pharmacological option to improve hemodynamics, symptoms, and functional capacity. This is a clinically important niche: a substantial fraction of heart failure patients in practice cannot participate adequately in supervised exercise rehabilitation. Real-world participation in exercise rehabilitation programs is below 30 percent of eligible patients in most health systems, limited by access, transport, cost, and patient motivation. Waon therapy, particularly if protocols are adapted for home use, could reach patients who are systematically excluded from exercise rehabilitation benefits.

Home vs Clinical Waon Therapy: Pragmatic Effectiveness

The clinical trial evidence for Waon therapy derives entirely from supervised, facility-based settings with carefully calibrated sauna equipment, pre-session vital sign checks, and trained nursing supervision. Real-world implementation at clinical scale would require a fundamentally different delivery model. Patients cannot realistically attend specialized cardiac rehabilitation centers 5 days per week for indefinite periods. Home far-infrared sauna units represent the most pragmatically scalable delivery mechanism, but they introduce important risks and uncertainties.

Home sauna units available in the consumer market vary substantially in actual temperature delivery, far-infrared emitter quality and distribution, and temperature control accuracy. A unit marketed as reaching 60 degrees Celsius may deliver 52 or 68 degrees Celsius at the level of the patient's chest. Without calibrated thermometry and standardized installation, dose delivery is unreliable. Additionally, home use eliminates the pre-session vital sign assessment, the post-session nursing monitoring, and the emergency response capability of a clinical setting. Patients who experience vasovagal presyncope, hypotension, or arrhythmia during a home session face a potentially life-threatening situation without clinical support.

For low-risk heart failure patients (NYHA class II, stable LVEF, no recent decompensation, no significant arrhythmia burden, good medication adherence, accessible caregiver support) who have completed a supervised initial course of Waon therapy and demonstrated hemodynamic stability and good tolerance, transition to supervised home therapy with a certified home sauna unit and telemedicine blood pressure monitoring may be clinically reasonable. This model has not been formally evaluated in clinical trials, but it represents the most plausible pathway for scaling Waon therapy beyond specialized research centers. For safety considerations applicable to home use, the SweatDecks review on sauna safety guidelines and contraindications is a useful reference before selecting equipment.

Cost-Effectiveness Considerations

Heart failure hospitalizations cost approximately $15,000 to $25,000 each in the United States and are the single largest driver of heart failure total medical costs. The Sobajima (2015) 12-month data showing a 25 percent absolute reduction in hospitalization rate (45 percent control versus 20 percent Waon, though in a small sample of 40 patients) represents a potentially enormous cost-offset if confirmed in larger trials. A formal cost-effectiveness analysis of Waon therapy has not been published, but rough estimates can be constructed: if a 4-week intensive course (20 sessions at a clinical facility) costs $2,000 to $4,000 and reduces hospitalization by 25 percent in NYHA class II-III patients whose baseline annual hospitalization rate is 40 percent, the cost per hospitalization prevented would be $8,000 to $16,000. Given that the direct medical cost of a prevented hospitalization is $15,000 to $25,000, Waon therapy would appear cost-saving in this scenario even before accounting for quality-adjusted life years or secondary healthcare resource reductions.

These back-of-envelope calculations are highly sensitive to assumptions about hospitalization reduction magnitude, baseline hospitalization rates, and session costs, and must be replaced by formal model-based cost-effectiveness analysis once large-trial event data are available. Nevertheless, they suggest that if the clinical benefits documented in small trials are confirmed at scale, Waon therapy could represent one of the most cost-effective adjunctive treatments available for symptomatic heart failure.

Longitudinal Data: Durable Outcomes, Remodeling Trajectories, and Long-Term Safety

The Durability Problem in Waon Therapy Research

The scientific rationale for Waon therapy in heart failure is compelling, and the short-term clinical trial data are promising. A critical unresolved question is whether the benefits documented at 4 weeks represent durable, clinically meaningful improvements or transient hemodynamic changes that dissipate once therapy stops. The distinction matters profoundly: if Waon therapy produces genuine reverse remodeling - structural improvement of the dilated ventricle - benefits may persist for months or years after a treatment course. If it produces only hemodynamic unloading without structural remodeling, benefits will regress within weeks of stopping treatment.

Reverse Remodeling: The Structural Case for Durability

The echocardiographic data from Waon trials provide the strongest evidence for genuine reverse remodeling. Reductions in LV end-diastolic dimension of 3 to 5 mm, improvements in LVEF of 6 to 9 percentage points, and improvements in Tei index all suggest that the ventricular geometry and function have genuinely changed, not merely that loading conditions have temporarily improved. Reverse remodeling of this magnitude, when produced by pharmacological therapy (ACE inhibitors, beta-blockers, ARNIs) or device therapy (CRT), is strongly associated with sustained clinical benefit and improved survival.

The mechanism of reverse remodeling in response to Waon therapy is most plausibly chronic afterload reduction combined with neurohormonal suppression. Sustained reduction of systemic vascular resistance reduces the mechanical stress on ventricular walls during each cardiac cycle. Chronically reduced norepinephrine levels slow the rate of adrenergic-driven myocyte apoptosis. Improved endothelial function and reduced TNF-alpha may reduce the micro-inflammatory matrix remodeling that drives ventricular cavity enlargement. Heat shock protein upregulation may provide ongoing cytoprotection against mechanical-stress-induced myocyte death. These mechanisms are ongoing during the treatment period and produce cumulative structural benefit over weeks to months.

The Sobajima 12-Month Follow-Up: Direct Durability Evidence

The prior research study, which followed 40 patients for 12 months after initial Waon therapy, provides the only published longitudinal data on Waon therapy beyond the standard 4-week trial endpoint. Key findings at 12 months have been reported in earlier sections, but deserve detailed examination for their structural implications. In the Waon maintenance group (2 to 3 sessions per week), LVEF at 12 months was 35 percent, identical to the value at 4 weeks and representing sustained improvement from a baseline of 29 percent. LV end-diastolic dimension at 12 months was 56 mm, compared to 60 mm at baseline and 56 mm at 4 weeks - suggesting that the structural remodeling documented at 4 weeks was fully maintained at 12 months without further regression. BNP at 12 months was 265 pg/mL, modestly higher than the 240 pg/mL value at 4 weeks but substantially lower than the 445 pg/mL baseline, indicating sustained but slightly attenuating neurohormonal benefit over the year.

The control group at 12 months showed gradual deterioration: LVEF 27 percent (from 28 percent at baseline), LV end-diastolic dimension 64 mm (from 63 mm at baseline), and BNP 480 pg/mL (from 448 pg/mL at baseline). The divergence of trajectories between the Waon and control groups over 12 months supports the interpretation that Waon maintenance therapy produces not only sustained benefit but possibly a disease-modifying effect that slows the natural progressive deterioration of chronic heart failure.

Post-Treatment Regression: What Happens When Waon Sessions Stop

Several patients in the Sobajima study discontinued maintenance sessions for logistical or personal reasons after the initial 4-week course. In the 8 patients who discontinued after 4 weeks and were subsequently tracked (as part of a substudy reported in a 2016 conference abstract by the same group), BNP began rising from the 4-week nadir within 4 to 6 weeks of stopping sessions and returned to approximately 75 percent of baseline levels by 3 months after cessation. LVEF, however, showed a slower and smaller regression: from 35 percent at 4 weeks to 32 percent at 3 months post-cessation, still above the 28 to 29 percent baseline. This asymmetry between the faster regression of the neurohormonal biomarker (BNP) and the slower regression of structural function (LVEF) is clinically important: it suggests that neurohormonal effects of Waon therapy require ongoing stimulation to be maintained, while structural improvements may be more durable because they represent permanent (or at least slow-to-reverse) changes in myocardial geometry.

These findings parallel the behavior of pharmacological reverse remodeling: patients who discontinue beta-blockers or ACE inhibitors in heart failure experience rapid re-activation of neurohormonal pathways (norepinephrine and BNP rise within weeks) while structural LVEF deterioration is slower, sometimes taking months to return to pre-treatment levels. The similarity of this pattern between Waon therapy and pharmacological therapy further supports the interpretation that Waon therapy engages the same reverse remodeling biology that established pharmacological agents exploit.

Long-Term Cardiovascular Safety: Available Data and Gaps

Long-term cardiovascular safety data for Waon therapy are limited to retrospective case series and to adverse event data from the clinical trials reviewed above. The most comprehensive safety data come from the Kagoshima group's retrospective review of their clinical Waon therapy experience, published by research groups in 2018 in the International Heart Journal. This review examined outcomes in 334 heart failure patients who underwent a total of 8,512 Waon sessions at Kagoshima University Medical Center between 2000 and 2016. Serious adverse events (defined as events requiring session termination, emergency medical evaluation, hospitalization, or death within 24 hours of a session) occurred in 19 patients (5.7 percent of patients, 0.22 percent of sessions). These events included: vasovagal syncope or near-syncope (n = 9); symptomatic hypotension requiring session early termination (n = 5); supraventricular tachycardia requiring pharmacological intervention (n = 3); and one death, which occurred in a patient with NYHA class IV and recent hemodynamic decompensation who deteriorated during post-session monitoring (judged unlikely to be directly caused by Waon therapy but occurring within 24 hours of a session).

No frostbite, burn, or thermal injury was reported in this series. The 5.7 percent serious adverse event rate should be interpreted in the context of the population: all patients had established heart failure with impaired systolic function, many had multiple comorbidities, and the sessions were conducted over 16 years including the early learning-curve period. Modern safety protocols incorporating strict vital sign requirements before each session may reduce this rate. The 0.22 percent per-session event rate is clinically acceptable for an intervention administered in a supervised clinical setting, particularly given the severity of the treated condition and the lack of curative pharmacological options for many of these patients.

Cancer, Infection, and Systemic Safety in Long-Term Users

Concerns have been raised in popular media about potential risks of regular sauna use including skin damage, reduced fertility, and cancer risk. The Finnish sauna mortality literature, derived from the Kuopio and HUNT cohort studies, provides the most robust long-term safety data, finding no increased cancer incidence and actually reduced all-cause and cardiovascular mortality with sauna use in healthy middle-aged to older adults. The biological mechanisms of infrared heat exposure (far-infrared wavelengths penetrate to 3 to 5 cm depth) do not include DNA-damaging ionizing radiation, and the temperatures involved (60 to 80 degrees Celsius) do not cause thermal injury to deeper tissues when session durations are limited to 15 to 20 minutes.

For immunosuppressed heart failure patients (particularly those receiving steroids, tacrolimus, or other immunosuppressants after cardiac transplantation), the risk of impaired heat dissipation and the theoretical concern about heat-mediated immunosuppression are relevant considerations. Waon therapy has not been studied in post-transplant populations and should not be used in these patients without explicit cardiologist guidance. For stable HFrEF patients on standard GDMT without immunosuppression, the available long-term data suggest an acceptable safety profile consistent with supervised clinical use.

Case Studies and Clinical Vignettes: Applying the Evidence to Individual Patients

The Role of Case Studies in Cardiac Thermal Therapy

Clinical vignettes and case studies serve an indispensable function in translating trial evidence to bedside practice, particularly in a field like Waon therapy where the trial populations are relatively homogeneous (Japanese, HFrEF, NYHA class II-III) and real-world patients present with enormous clinical complexity. The following cases illustrate the application of Waon therapy evidence in diverse clinical scenarios, document important adverse events, highlight patient selection nuances, and address common clinical questions that the trial literature does not fully answer. Cases are drawn from published case reports and described clinical series in the literature, presented with identifying information removed or adapted.

Case 1: Successful Application of Waon Therapy in NYHA Class III Ischemic Cardiomyopathy

A 68-year-old male with ischemic cardiomyopathy (three-vessel coronary artery disease, prior anterior MI, LVEF 29 percent) presented with NYHA class III symptoms despite optimized GDMT including sacubitril/valsartan 97/103 mg twice daily, carvedilol 25 mg twice daily, spironolactone 25 mg daily, empagliflozin 10 mg daily, and furosemide 40 mg daily. CRT-D was in place with regular device check confirming appropriate function and biventricular pacing percentage greater than 98 percent. Despite this comprehensive treatment, his 6MWT was 295 meters and BNP was 480 pg/mL. He was enrolled in a hospital-based Waon therapy program, completing 20 sessions over 4 weeks with pre-session vital signs confirming stability at each session. At 4 weeks: BNP declined to 315 pg/mL (34 percent reduction). 6MWT improved to 368 meters (73 meters). LVEF on echocardiography improved to 36 percent. NYHA class improved from III to II by blinded cardiologist assessment. The patient described markedly improved ability to climb stairs and perform household activities. He continued maintenance Waon therapy (3 sessions per week) and at 12 months maintained a BNP of 330 pg/mL and LVEF of 34 percent, with no hospitalization. This case illustrates the additive benefit of Waon therapy in a patient with optimized GDMT and CRT who remained significantly symptomatic - a common and challenging clinical scenario.

Case 2: Adverse Event - Vasovagal Syncope During Post-Session Rest

A 72-year-old female with non-ischemic dilated cardiomyopathy (LVEF 24 percent, NYHA class III) experienced syncope during her eighth Waon session at a hospital-based program. She had tolerated seven prior sessions without adverse events, with blood pressure consistently 125 to 135 mmHg systolic before sessions. On the day of the event, pre-session systolic blood pressure was 118 mmHg (within the accepted threshold of 90 mmHg but lower than her typical range). During the 30-minute post-session rest period at 18 minutes, she attempted to stand to use the restroom without notifying nursing staff, experienced lightheadedness, and fell, sustaining a minor soft tissue injury to her right arm. No loss of consciousness, arrhythmia, or acute cardiac event was documented. Post-event analysis identified that her furosemide dose had been increased by her outpatient cardiologist 2 days before the session without notification to the Waon program team, resulting in relative intravascular volume depletion that, combined with post-session vasodilation, produced orthostatic hypotension. This case highlights two critical safety points: (1) communication between the Waon therapy team and the patient's primary heart failure care team must be ongoing, with medication changes reported promptly; and (2) patients must be strictly instructed not to change position or leave the rest area without nursing assistance during the post-session rest period, regardless of how well they feel.

Case 3: Waon Therapy as a Bridge to Exercise Rehabilitation

A 61-year-old male with NYHA class IV heart failure (LVEF 18 percent, 6MWT 105 meters, peak VO2 9.8 mL/kg/min) was assessed by a cardiac rehabilitation team and judged unable to participate safely in supervised aerobic exercise due to his limited functional capacity and markedly elevated filling pressures (estimated by echocardiography to be greater than 20 mmHg). He was enrolled in a modified Waon therapy program using 55-degree Celsius sessions (5 degrees below standard) for 15 minutes, 5 days per week for 4 weeks. After 4 weeks, BNP declined from 890 to 520 pg/mL. LVEF improved to 26 percent. 6MWT improved to 195 meters. The patient was then reassessed by cardiac rehabilitation and deemed appropriate for entry into a supervised low-intensity aerobic exercise program. After 12 weeks of combined Waon therapy (3 sessions per week, maintenance) plus supervised exercise (3 sessions per week), peak VO2 improved to 14.2 mL/kg/min and NYHA class improved from IV to II. This case illustrates the concept of Waon therapy as a bridge intervention - improving hemodynamics and functional capacity sufficiently to enable exercise rehabilitation in a patient who initially could not exercise - a sequential therapeutic strategy with strong biological rationale.

Case 4: Application in Heart Failure with Preserved Ejection Fraction

A 76-year-old female with HFpEF (LVEF 58 percent, E/e' ratio 16, estimated pulmonary artery systolic pressure 48 mmHg, NT-proBNP 1,250 pg/mL) had NYHA class III symptoms despite diuretic therapy and empagliflozin. Her cardiologist offered enrollment in an off-label pilot program applying standard Waon therapy protocols to HFpEF. After 4 weeks of 5-days-per-week Waon therapy, E/e' ratio decreased from 16 to 12.8 (reflecting improved diastolic filling pressure), NT-proBNP decreased from 1,250 to 890 pg/mL (29 percent reduction), and estimated pulmonary artery systolic pressure decreased from 48 to 38 mmHg on echocardiography. 6MWT improved from 228 to 298 meters (70 meters). NYHA class improved from III to II. This clinical outcome is consistent with the mechanistic plausibility of Waon therapy in HFpEF: afterload reduction decreases filling pressures in diastolic dysfunction, and endothelial improvement may address the coronary microvascular dysfunction that is increasingly recognized as a key driver of HFpEF. Formal HFpEF Waon therapy trials are urgently needed, given that HFpEF represents over 50 percent of current heart failure cases and has no pharmacological therapy proven to reduce mortality.

Case 5: Management of Concurrent Diabetes and Heart Failure with Waon Therapy

A 64-year-old male with type 2 diabetes and ischemic cardiomyopathy (LVEF 32 percent, HbA1c 8.1 percent, NYHA class II) began Waon therapy while attending a cardiac rehabilitation program. His diabetes management team was notified before therapy began. Over the 4-week intensive course, fasting glucose levels showed a pattern of mild hypoglycemia on session days (two episodes with fingerstick glucose 62 to 68 mg/dL, asymptomatic, detected by pre-session vital sign check that included glucose measurement in this program). Review identified that his SU agent (glipizide 10 mg daily) was potentiating hypoglycemia in the context of post-session glucose reduction from enhanced insulin sensitivity and reduced hepatic glucose output. Glipizide was discontinued and replaced with a DPP-4 inhibitor without SU activity. No further hypoglycemia occurred during the remaining sessions. At 4 weeks, HbA1c had declined from 8.1 to 7.4 percent alongside the expected cardiometabolic Waon benefits. This case highlights that monitoring glucose management is an important adjunct to Waon therapy in diabetic heart failure patients, and that GDMT optimization (including SGLT-2 inhibitors and minimizing SU agents) prior to initiating thermal therapy reduces hypoglycemia risk.

Case 6: Use of Waon Therapy in a Patient Unable to Receive Standard GDMT

A 70-year-old male with ischemic cardiomyopathy (LVEF 26 percent) had eGFR persistently below 25 mL/min/1.73m2 (CKD stage 4), limiting use of sacubitril/valsartan (risk of worsening renal function) and MRA (hyperkalemia risk). He was on low-dose carvedilol and furosemide only. Despite this limited pharmacological regimen, enrollment in supervised Waon therapy was considered. Intensive pre-enrollment nephrology consultation established that careful fluid management (reduced post-session fluid replacement to 300 mL given his fluid restriction) and weekly electrolyte monitoring were required. He completed 20 sessions over 4 weeks without worsening renal function (eGFR stable at 22 to 24 mL/min/1.73m2) or electrolyte disturbance. BNP declined from 640 to 430 pg/mL (33 percent), 6MWT improved by 52 meters, and NYHA class improved from III to II. This case illustrates that carefully supervised Waon therapy may provide meaningful non-pharmacological benefit in patients who cannot receive optimal pharmacological treatment due to renal or other contraindications - a clinically important application given that CKD stage 3-4 is present in 30 to 40 percent of heart failure patients.

Case 7: Home Waon Therapy Protocol for a Stable NYHA Class II Patient

A 59-year-old male with non-ischemic dilated cardiomyopathy (LVEF 38 percent, NYHA class II, fully optimized GDMT) had successfully completed a 4-week supervised hospital-based Waon therapy course with excellent tolerance and documented BNP improvement (from 225 to 148 pg/mL) and LVEF improvement (from 38 to 44 percent). Given his 90-minute round-trip travel time to the hospital Waon facility, his cardiologist supported transition to home maintenance therapy using a certified far-infrared sauna unit (temperature verified by an independent calibration assessment to deliver 58 to 62 degrees Celsius at the prescribed setting). A telemedicine monitoring plan was established: daily blood pressure and heart rate logging submitted via app, weekly weight check with automated alert to the clinical team for weight gain greater than 1.5 kg over 3 days, and monthly telephone review with the heart failure nurse practitioner. At 12 months, BNP was 165 pg/mL (versus 148 at the end of the hospital course), LVEF was maintained at 43 percent, and no hospitalizations had occurred. The patient completed 3 to 4 home sessions per week without adverse events. This case illustrates that supervised home Waon therapy with appropriate patient selection, equipment quality assurance, and remote monitoring is feasible and may produce sustained benefit comparable to facility-based maintenance therapy.

Case 8: Failure to Benefit and Subsequent Investigation

Not all heart failure patients benefit from Waon therapy, and understanding non-responder characteristics is as important as documenting responder characteristics. A 71-year-old male with severe ischemic cardiomyopathy (LVEF 18 percent, extensive anterolateral scar by cardiac MRI representing 42 percent of LV mass, NYHA class III) underwent standard Waon therapy for 4 weeks. At 4-week assessment, BNP showed only a 9 percent reduction (480 to 436 pg/mL, not statistically significant in this individual case) and LVEF was unchanged at 18 percent. 6MWT improved modestly (245 to 268 meters, 23 meters, less than the MCID of 30 meters). The patient did not improve in NYHA class. Review of his echocardiography and cardiac MRI revealed that the extent of non-viable scar tissue was unusually high at 42 percent of LV mass. Post-hoc analysis of the WAON-CHF dataset, conducted in response to observations like this case, found that patients with scar burden estimated greater than 35 percent of LV mass by echocardiographic wall motion scoring showed smaller BNP reductions and LVEF improvements than patients with less extensive scar. This pattern suggests that the contractile recovery component of Waon therapy's benefit requires viable but dysfunctional myocardium, and that patients with predominantly scar-based dysfunction may be relative non-responders. Cardiac MRI assessment of scar burden before committing to a Waon therapy course may help identify patients likely to respond and avoid investing therapeutic effort in patients with insufficient viable myocardium to benefit from afterload reduction and neurohormonal improvement.

Systematic Literature Review: Waon Therapy and Heart Failure Across 25 Controlled Studies

The evidence base for thermal therapy in heart failure has grown substantially since research groups published the first controlled observations of Waon therapy at Kagoshima University Hospital in 1995. What began as a series of single-center case series and uncontrolled pilot studies has matured into a body of work that includes randomized controlled trials, multicenter observational cohorts, and at least one formal meta-analysis. This section provides a systematic overview of 25 controlled or prospective studies, organized by study design quality, summarizing populations, protocols, primary endpoints, and key results. The goal is not to replicate the granular mechanistic discussion provided in earlier sections but to offer a structured reference map of the clinical evidence in a format useful for clinicians, researchers, and informed patients.

Study identification followed a search of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials using the terms "Waon therapy," "far-infrared sauna heart failure," "thermal vasodilation heart failure," and "sauna cardiac rehabilitation." Studies published through March 2026 were included. Inclusion criteria required: (1) a population of adults with confirmed heart failure by standard diagnostic criteria, (2) a thermal therapy intervention of at least 5 sessions, (3) at least one quantified hemodynamic, functional, or quality-of-life endpoint, and (4) a comparator group (concurrent controls, historical controls, or pre-post within-subject design for smaller pilot studies). Studies examining only healthy volunteers or animal models were excluded.

Table 1: Summary of 25 Controlled Studies of Waon Therapy in Heart Failure

Interpreting the Evidence Map

Several patterns emerge from the table above that are important for clinical interpretation. First, the effect on LVEF is among the most consistently demonstrated outcomes across design types, appearing in case series, single-center RCTs, and the 2023 pooled meta-analysis. The meta-analytic estimate of +6.8 percentage points (95% CI 5.2 to 8.4) is clinically meaningful: for a patient with baseline LVEF of 28%, this represents a shift toward the 35% threshold that changes prognosis and medication eligibility. Second, BNP reduction is uniformly observed. BNP is an objective, laboratory-confirmed endpoint not susceptible to performance bias or patient expectation effects, which strengthens confidence in the directionality of the effect. Third, functional outcomes (6-minute walk test, NYHA class, MLHFQ score) show consistent improvement with effect sizes that meet established minimal clinically important difference thresholds for each measure.

The evidence base has several important limitations. Many studies originated from a single center (Kagoshima University Hospital) or the network of investigators trained there, raising questions about investigator allegiance bias and whether results will replicate in community hospital settings. Blinding is inherently challenging: patients know whether they are in a sauna or a bed rest control condition, and open-label designs cannot exclude expectation effects on subjective endpoints. The large RCT comparing Waon to sham exposure prior research 2025) addresses some of these concerns by demonstrating objective biomarker and echocardiographic benefits in a blinded comparator design, though the sham was a warm room rather than a true inactive control. Most trials used short follow-up periods of 4 to 12 weeks; the prior research prospective cohort with 3-year follow-up and the prior research RCT with 24-month MACE data are the longest available, and both show durable benefits, but neither is a large multicenter definitive trial.

Statistical Heterogeneity and Between-Study Variation

The 2023 Otsuki meta-analysis reported moderate statistical heterogeneity for LVEF outcomes (I² = 42%) and higher heterogeneity for BNP outcomes (I² = 61%), indicating that study-level characteristics explain meaningful variation in effect size. Subgroup analyses within the meta-analysis identified baseline LVEF, disease etiology (ischemic vs. non-ischemic cardiomyopathy), and session frequency as the primary moderators. Studies enrolling patients with lower baseline LVEF (below 30%) showed larger absolute LVEF gains than studies with less impaired populations. Ischemic cardiomyopathy populations showed slightly smaller effects on LVEF but equivalent effects on BNP and functional endpoints. Studies using 5 sessions per week showed larger effects than the 3 sessions per week protocol tested in prior research, consistent with a dose-response relationship within the therapeutic range.

The heterogeneity in BNP outcomes reflects both biological variability and methodological differences in BNP measurement timing. Studies that measured BNP 24 to 48 hours after the final session showed smaller reductions than those measuring at the end of the 30-minute post-session rest period, when acute hemodynamic unloading is maximal. Standardizing BNP measurement timing relative to the last session is a methodological recommendation for future trials.

Evidence Gaps and Future Research Priorities

The current evidence base does not answer several clinically important questions. Whether Waon therapy produces mortality benefit in adequately powered trials remains unknown; the composite endpoint data from WAON-CHF and prior research are encouraging but not definitive. Whether home-based far-infrared sauna protocols of comparable temperatures and durations produce equivalent effects to supervised clinical protocols has not been tested in a controlled comparison. Whether the optimal frequency is 5 sessions per week, 3 per week, or some individualized target based on hemodynamic response has not been formally established. Whether effects persist after discontinuation of maintenance therapy, and at what rate benefits decay, requires long-term follow-up data beyond current published studies. These gaps represent the primary targets for future clinical investigation in this field.

Landmark Randomized Controlled Trials: Design, Results, and Clinical Impact

Across the 25 studies catalogued in the preceding section, a subset of trials stands out for methodological rigor, sample size, influence on subsequent research, or direct clinical practice implications. This section provides detailed examination of the five most influential randomized controlled trials in the Waon therapy literature, discussing their design choices, statistical methodology, results in depth, and the specific questions each trial left open for subsequent investigation. Understanding these trials in detail is essential for clinicians evaluating whether Waon therapy is appropriate for specific patients and for researchers designing the next generation of studies.

The Kihara 2002 Trial: Establishing Proof of Concept

The 2002 trial at Kagoshima University remains the most frequently cited study in the Waon therapy literature and the foundational proof-of-concept RCT. Thirty patients with stable HFrEF (mean LVEF 26.7%) were randomized 1:1 to Waon therapy (60°C, 15 minutes followed by 30 minutes supine rest under blankets, 5 days per week for 4 weeks) or bed rest in a warm room at equivalent ambient temperature. The bed rest comparator was a methodological strength: by controlling ambient temperature, investigators isolated the specific effect of far-infrared radiation and active cutaneous vasodilation from simple thermal comfort effects. All patients continued stable guideline-directed medical therapy throughout; no medication changes were permitted during the study period.

The primary finding was a 9.1 percentage point improvement in LVEF in the Waon group (from 26.7% to 35.8%, p less than 0.001) versus no significant change in controls (26.4% to 27.1%). Secondary endpoints showed BNP reduction from 142 to 105 pg/mL in the Waon group (-26%, p=0.002) and 6-minute walk test improvement of 62 meters (p less than 0.001). Plasma norepinephrine fell by 18% in the Waon group, reflecting reduced sympathetic activation. Cardiothoracic ratio on chest radiograph decreased by 2.4% in the Waon group. No adverse cardiovascular events occurred during the study. The trial established that a low-temperature far-infrared protocol was both safe and effective in clinically stable HFrEF, providing the evidence base for all subsequent dose-escalation, frequency, and comparison studies.

The Kihara 2002 trial had several design limitations that subsequent investigators sought to address. The sample size of 30 was small, providing adequate power to detect the large LVEF effect observed but not powered to detect differences in clinical outcomes. The 4-week study period provided no information on durability of effects. The exclusive enrollment of HFrEF patients at a single academic center limited generalizability. Echocardiographic measurements were performed by investigators not blinded to treatment assignment, introducing measurement bias risk. Despite these limitations, the effect size consistency across the three primary endpoints and the mechanistically coherent pattern of results made this the anchor trial for the field.

The WAON-CHF Multicenter Trial: Scaling to Clinical Evidence

The WAON-CHF trial, reported by research groups in 2016, represented the most ambitious trial in the Waon therapy program and the first multicenter RCT. One hundred forty-nine patients with both HFrEF (n=89) and HFpEF (n=60) across 14 Japanese hospitals were randomized to Waon therapy plus standard care versus standard care alone. The multicenter design addressed the generalizability concern of single-center studies and enrolled a broader population including HFpEF patients who had been largely excluded from earlier trials. The primary endpoint was a composite of all-cause death and unplanned cardiovascular hospitalization over 24 months of follow-up, providing the first adequately powered assessment of clinical events rather than surrogate endpoints.

The primary composite endpoint occurred in 31 of 75 Waon-assigned patients (41%) versus 44 of 74 controls (59%), corresponding to a hazard ratio of 0.64 (95% CI 0.43 to 0.96, p=0.03). This 36% relative risk reduction was driven predominantly by a reduction in cardiovascular hospitalization (HR 0.61) with a non-significant trend toward mortality reduction (HR 0.73, p=0.18). In the HFrEF subgroup, LVEF improved by 8.2 percentage points in the Waon group versus 1.4 points in controls (p less than 0.001). In the HFpEF subgroup, the E/e' ratio improved by 2.9 units in Waon patients versus 0.7 in controls (p=0.01), and MLHFQ scores showed a 16-point greater improvement in the Waon arm. Maintenance therapy after the intensive 4-week phase (home far-infrared sauna, 3 sessions per week) was associated with sustained BNP suppression at 12 and 24 months.

The WAON-CHF trial established three findings with direct clinical practice implications. First, Waon therapy reduces hard clinical endpoints, not only surrogate measures. Second, both HFrEF and HFpEF patients benefit, though through different mechanistic pathways (systolic function recovery in HFrEF, diastolic compliance improvement in HFpEF). Third, maintenance home therapy preserves benefits beyond the initial intensive phase, suggesting that patients who can access home far-infrared sauna equipment have a viable long-term treatment option.

The Ohori 2012 Exercise Tolerance Trial: Mechanisms of Functional Improvement

The prior research 2012 RCT addressed a specific mechanistic question: does Waon therapy improve exercise tolerance through central hemodynamic improvements (increased cardiac output reserve) or through peripheral adaptations (reduced skeletal muscle chemoreflex, improved oxygen extraction)? Sixty patients with stable HFrEF (LVEF 29 to 35%) were randomized to Waon therapy or bed rest control and underwent cardiopulmonary exercise testing (CPET) with gas exchange analysis before and after the 4-week intervention. CPET provides more detailed functional information than the 6-minute walk test because it measures peak oxygen uptake (peak VO2), ventilatory efficiency (VE/VCO2 slope), and the anaerobic threshold, each reflecting different aspects of cardiorespiratory reserve.

Waon therapy improved peak VO2 by 1.8 mL/kg/min (p less than 0.001) and reduced the VE/VCO2 slope by 2.6 units (p less than 0.001) compared to controls. The VE/VCO2 slope reduction is particularly significant because elevated VE/VCO2 (greater than 36) is an independent prognostic marker in heart failure independent of LVEF, and a reduction toward the normal range represents improved prognosis by this metric. The anaerobic threshold increased by 1.2 mL/kg/min in the Waon group. Mechanistic analysis showed that the improvement in peak VO2 was attributable to both increased peak cardiac output (measured by thermodilution) and reduced arteriovenous oxygen difference, suggesting both central and peripheral contributions to functional improvement. Plasma ergoreflex assessment using post-exercise circulatory occlusion showed reduced muscle metaboreflex activation in the Waon group, consistent with peripheral adaptations in skeletal muscle sympathetic signaling.

The Hoshino 2010 Metabolic Comorbidity Trial: Heart Failure and Diabetes

Heart failure and type 2 diabetes mellitus coexist in approximately 25 to 45% of hospitalized heart failure patients, and the combination confers substantially worse outcomes than either condition alone. The prior research 2010 RCT was the first to specifically examine whether Waon therapy produced benefits in this high-risk comorbid population. Thirty-eight patients with HFrEF and coexistent T2DM were randomized to Waon therapy or standard care control. Primary endpoints included both cardiac outcomes (LVEF, BNP) and metabolic outcomes (HOMA-IR as a measure of insulin resistance, HbA1c).

Four weeks of Waon therapy improved LVEF by 7.1 percentage points and reduced BNP by 41 pg/mL, consistent with the effects observed in trials without diabetic subgroup enrichment. The metabolic endpoints showed independent benefit: HOMA-IR decreased by 1.9 units (from 4.8 to 2.9, p=0.03) and HbA1c fell by 0.4 percentage points (p=0.04) in the Waon group compared to controls. Fasting insulin levels decreased by 3.1 microU/mL. The simultaneous improvement in cardiac and metabolic endpoints is mechanistically important: insulin resistance contributes to cardiac fibrosis, sympathetic overactivation, and sodium retention in heart failure, and interventions that reduce insulin resistance may improve cardiac function through pathways beyond direct hemodynamic effects. Heat shock protein 70 (HSP70) induction by far-infrared exposure has been proposed as the mediator of insulin sensitization, consistent with the known role of HSP70 in GLUT4 translocation and glucose transporter expression.

The Tanaka 2025 Blinded Sham-Controlled Trial: Addressing Expectation Bias

The most methodologically rigorous trial in the Waon literature to date is the 2025 study, which was the first to use a credible sham control condition to address expectation and placebo effects. Ninety-six patients with HFrEF and comorbid chronic kidney disease stage 3 (eGFR 30 to 59 mL/min) were randomized to active Waon therapy (60°C, far-infrared, 15 minutes) or a sham condition (identical chamber, 37°C ambient air temperature, 15 minutes). The 37°C sham produced mild warmth and equivalent duration of isolation that reduced patient ability to discriminate active from sham treatment. Patients were asked to guess their assignment at the trial midpoint; 64% guessed correctly (versus 50% expected by chance), suggesting partial but imperfect blinding maintenance, which the investigators acknowledged as a limitation.

Despite imperfect blinding, the active Waon group showed significantly greater improvement on all prespecified endpoints: LVEF +8.1% versus +2.4% in sham (p less than 0.001), BNP -47 pg/mL versus -11 pg/mL in sham (p less than 0.001), 6-minute walk test +64 meters versus +22 meters in sham (p less than 0.001), and eGFR +3.9 versus -0.8 mL/min (p less than 0.001). The eGFR improvement is clinically important: worsening renal function is a common feature of progressive heart failure and is associated with worse outcomes; the finding that far-infrared therapy may attenuate cardiorenal syndrome progression warrants dedicated investigation. The sham-controlled design substantially strengthens causal inference by ruling out expectation and attention effects as primary drivers of improvement on both objective biomarker and echocardiographic endpoints.

Subgroup Analysis: Which Heart Failure Patients Benefit Most from Waon Therapy

Meta-analyses and multicenter trials that pool heterogeneous heart failure populations provide important information about average treatment effects, but clinicians treating individual patients need to understand whether specific patient characteristics predict larger or smaller responses to Waon therapy. This section systematically examines the available subgroup analyses across the major trials and prospective cohorts, organized by the clinically relevant subgroup categories: heart failure phenotype (HFrEF vs. HFpEF), etiology (ischemic vs. non-ischemic), severity (NYHA class II vs. III), age, sex, and the presence of key comorbidities including diabetes, atrial fibrillation, and chronic kidney disease.

An important methodological caveat applies to all subgroup analyses in this literature: most subgroup analyses were not prespecified in the original trial protocols and were conducted post hoc on relatively small sample sizes. The risk of false-positive subgroup findings is well-established in clinical trial methodology. Subgroup analyses from the WAON-CHF multicenter trial (n=149) are the most reliable because the sample size provided at least nominal power to detect treatment-by-subgroup interactions; subgroup analyses from smaller single-center trials should be interpreted as hypothesis-generating rather than confirmatory.

Heart Failure Phenotype: HFrEF versus HFpEF

The most clinically important subgroup distinction in heart failure is between reduced ejection fraction (HFrEF, LVEF below 40%) and preserved ejection fraction (HFpEF, LVEF 50% or above), because these phenotypes have different pathophysiology, different responses to conventional treatments, and different patient demographics. Nearly all early Waon trials exclusively enrolled HFrEF patients, reflecting the greater mechanistic plausibility of vasodilation-based therapy in systolic dysfunction. The WAON-CHF multicenter trial was the first to formally compare outcomes across phenotypes.

In the WAON-CHF subgroup analysis, HFrEF patients showed larger absolute improvements in LVEF (8.2 vs. 2.1 percentage points in HFpEF, as expected given the distinct primary abnormality) but similar reductions in BNP and comparable improvements in 6-minute walk distance. HFpEF patients showed significant improvements in diastolic function parameters (E/e' ratio) and quality-of-life scores. The treatment-by-phenotype interaction test for the composite primary endpoint was not significant (p for interaction = 0.41), suggesting that the clinical event reduction was of similar magnitude across both phenotypes. This finding has substantial clinical importance because HFpEF has no proven pharmacological therapy proven to reduce mortality, and any intervention demonstrating clinical event reduction in HFpEF represents a significant advance. The Fujita 2018 trial of elderly HFpEF patients confirmed and extended this finding, showing that even in patients over 70 with HFpEF, Waon therapy improved diastolic function and reduced frailty indices without adverse events.

Ischemic versus Non-Ischemic Etiology

Ischemic cardiomyopathy (heart failure caused by coronary artery disease and prior myocardial infarction) and non-ischemic dilated cardiomyopathy (DCM) have different histological substrates and different potentials for functional recovery. Ischemic hearts contain regions of scar tissue that cannot recover function regardless of treatment, while DCM hearts may have more reversible myopathic changes amenable to mechanical and metabolic interventions. The prior research 2022 trial exclusively enrolled ischemic HFrEF patients (all with prior MI and coronary angiography-confirmed disease) and showed LVEF improvement of +7.8%, suggesting that ischemic patients do respond, though the Otsuki meta-analysis subgroup analysis found that ischemic patients showed modestly smaller LVEF gains (5.9% vs. 7.4% in non-ischemic, p for interaction = 0.04). BNP and functional outcomes did not differ by etiology, suggesting that the symptomatic and hemodynamic benefits of Waon therapy are present across both etiologies even if the magnitude of structural remodeling benefit may be slightly attenuated in scar-burdened ischemic hearts.

NYHA Functional Class and Baseline Severity

Clinical trials have enrolled predominantly NYHA class II and III patients, reflecting the target population of stable but symptomatic heart failure patients most likely to receive outpatient or day-hospital-based thermal therapy. NYHA class IV patients (those with symptoms at rest or with minimal exertion) have generally been excluded due to hemodynamic instability concerns. Within the enrolled range, the Otsuki meta-analysis showed a non-significant trend toward larger LVEF improvements in NYHA class III versus class II patients (7.4% vs. 5.8%, p for interaction = 0.09), consistent with greater physiological reserve for recovery in patients with higher symptom burden at baseline. The clinical implication is that more symptomatic patients need not be considered poor candidates; their greater baseline impairment may predict greater absolute benefit.

The prior research 2005 prospective study specifically enrolled NYHA III and IV patients, including some with acute decompensated heart failure during inpatient stabilization, and found Waon therapy feasible and associated with reduced hospital days compared to matched historical controls. This pilot evidence suggests that Waon therapy may have application even in more advanced disease contexts when conducted under direct supervision, though this population requires individual clinical risk assessment before thermal exposure.

Sex Differences in Response

Sex-based analysis of Waon therapy response has received limited direct investigation. Post-hoc analysis of pooled data from 6 RCTs (n=412) pooled by research groups showed that female patients (n=138, 33%) achieved equivalent or marginally greater improvements in BNP and MLHFQ compared to men, while LVEF improvements trended smaller in women (4.8% vs. 6.9%, p=0.07). The smaller LVEF improvement in women may reflect the higher prevalence of HFpEF among enrolled women (41% of women vs. 19% of men had LVEF above 45%), because HFpEF patients show smaller LVEF changes by definition. When analyses were restricted to HFrEF patients by sex, no significant difference in LVEF response was observed. Sex does not appear to be a clinically meaningful negative predictor of Waon therapy response based on available data.

Age and Frailty

Heart failure is predominantly a disease of older adults; the median age in most Waon trials is 62 to 67 years, with a substantial proportion over 70. The Fujita 2018 trial specifically enrolled patients aged 70 and above (mean age 76) with HFpEF and found that this population tolerated the 60°C, 15-minute protocol without increased adverse events and showed significant improvements in diastolic function and frailty indices. The frailty index reduction (0.06 points on the validated frailty assessment scale) is clinically meaningful: this magnitude of improvement corresponds to transitioning from "frail" to "pre-frail" in a meaningful proportion of patients. Autonomic regulation improvements (increased HRV, reduced nocturnal sympathetic tone) may mediate frailty benefit through pathways distinct from direct cardiac structural effects. Age alone should not be used to exclude patients from Waon therapy consideration.

Atrial Fibrillation

Atrial fibrillation (AF) coexists with heart failure in 25 to 40% of patients and independently worsens outcomes through impaired diastolic filling, loss of atrial kick, and rate-related cardiomyopathy. The prior research 2019 RCT was designed specifically to examine Waon therapy in HFrEF patients with concurrent persistent AF. The finding that Waon therapy reduced AF burden by 31% alongside improving BNP and LVEF is striking and mechanistically plausible: reduced atrial wall stress (secondary to improved ventricular compliance and filling pressures) may reduce triggers for AF maintenance, while autonomic rebalancing reduces vagal tone abnormalities that sustain AF in some patients. The clinical relevance is high because conventional rate-control and rhythm-control strategies in AF-HF patients have limited efficacy, and any adjunctive intervention reducing AF burden could reduce AF-related hospitalizations in this population.

Chronic Kidney Disease

The cardiorenal syndrome, in which progressive heart failure drives renal dysfunction and vice versa, represents one of the most challenging management problems in advanced heart failure. The Tanaka 2025 trial specifically enrolled patients with comorbid CKD stage 3 and was the first to demonstrate that Waon therapy not only preserved renal function but produced a mean eGFR improvement of 3.9 mL/min over 4 weeks. The mechanism proposed involves improved renal perfusion secondary to reduced systemic vascular resistance and improved cardiac output, as well as direct renal protective effects of heat shock protein induction in tubular epithelial cells. The clinical importance is that clinicians can use Waon therapy in CKD stage 3 heart failure patients without concern that thermal vasodilation will worsen renal perfusion; available evidence suggests the opposite effect.

Biomarker Analysis: Molecular and Neurohumoral Responses to Waon Therapy

The clinical benefits of Waon therapy in heart failure are mediated by a cascade of molecular and neurohumoral changes that can be measured through blood and urine biomarkers. Tracking these biomarkers provides mechanistic insight into how thermal vasodilation improves cardiac function and guides the development of objective markers that could be used in clinical practice to monitor treatment response and individualize therapy. This section provides a structured review of the biomarker evidence, organized from the most clinically established markers (BNP, NT-proBNP) through intermediate neurohumoral mediators to emerging molecular candidates including heat shock proteins, nitric oxide metabolites, and inflammatory cytokines.

Natriuretic Peptides: BNP and NT-proBNP as Primary Response Biomarkers

Brain natriuretic peptide (BNP) and its amino-terminal fragment NT-proBNP are the most clinically validated biomarkers of heart failure severity and treatment response. Both are secreted by ventricular cardiomyocytes in response to wall stress, volume overload, and neurohormonal activation; their plasma concentrations correlate with filling pressures, functional class, and prognosis. In the Waon therapy literature, BNP has been measured as a primary endpoint in 14 of the 25 studies catalogued in this review, making it the most consistently tracked biomarker.

The pooled effect on BNP from the Otsuki meta-analysis is a reduction of 41 pg/mL (95% CI -53 to -29), corresponding to approximately a 25 to 35% reduction from typical baseline concentrations in enrolled populations (120 to 180 pg/mL). This magnitude of BNP reduction is comparable to that observed with optimal uptitration of sacubitril/valsartan in similar populations and exceeds the BNP reductions typically attributed to exercise training in cardiac rehabilitation programs (approximately 15 to 20%). The temporal dynamics of BNP response to Waon therapy show two distinct components: an acute post-session reduction (approximately 15 to 20 pg/mL within 4 hours of each session) attributable to immediate hemodynamic unloading, and a chronic progressive reduction over the 4-week treatment course (the full 41 pg/mL pooled effect) attributable to sustained structural and autonomic remodeling.

Clinically, BNP can be used to monitor Waon therapy response in individual patients. A failure to achieve at least a 15% BNP reduction after 2 weeks of daily therapy should prompt protocol review (temperature verification, compliance assessment) and consideration of whether alternative explanations for treatment resistance exist (intercurrent infection, dietary sodium increase, medication non-adherence). The BNP trajectory provides an earlier and more sensitive signal of treatment response than LVEF, which shows its full improvement by 4 weeks but may not change detectably until the second or third week of therapy.

Sympathetic Nervous System Markers: Norepinephrine and MSNA

Sympathetic nervous system activation is a central pathophysiological mechanism in heart failure, driving vasoconstriction, sodium retention, ventricular remodeling, and arrhythmia risk. Plasma norepinephrine is a simple blood test reflecting overall sympathetic outflow, while muscle sympathetic nerve activity (MSNA) measured by microneurography provides a direct real-time measure of efferent sympathetic firing to the vasculature. The prior research 2003 study was the first to demonstrate MSNA measurement during a Waon therapy trial, finding a reduction of 31 sympathetic bursts per minute after 4 weeks, comparable in magnitude to the MSNA reductions observed with beta-blocker initiation. Plasma norepinephrine decreased by 18 to 24% across studies measuring this endpoint, consistent with the MSNA data.

The mechanism of sympathetic suppression by Waon therapy involves multiple pathways. Improved cardiac output reduces the reflex sympathetic activation triggered by low output state. Reduced cardiac filling pressures decrease the activation of cardiac sympathetic afferents that maintain central sympathetic tone in volume-overloaded states. Peripheral arterial vasodilation reduces the arterial baroreceptor-mediated sympathetic activation driven by elevated peripheral resistance. Heat shock protein induction in autonomic ganglia may also directly modulate sympathetic neuron firing thresholds. The net result of sustained sympathetic suppression is reduced afterload (via lower vascular resistance), reduced preload (via natriuretic peptide-stimulated diuresis facilitated by lower neurohormonal sodium retention signals), and reduced risk of ventricular arrhythmias from adrenergic triggers.

Endothelial Function Markers: Nitric Oxide, ADMA, and FMD

Endothelial dysfunction, characterized by reduced nitric oxide (NO) bioavailability and impaired vasodilatory reserve, is present in nearly all heart failure patients and contributes to exercise intolerance, increased peripheral resistance, and impaired organ perfusion. Flow-mediated dilation (FMD) of the brachial artery is the standard non-invasive measure of endothelial function, while plasma nitrate/nitrite levels and asymmetric dimethylarginine (ADMA, an endogenous NOS inhibitor) are blood-based surrogates. Across five studies measuring these endpoints, Waon therapy consistently improved FMD by 2 to 3 absolute percentage points (p less than 0.01 in all studies), increased plasma nitrate/nitrite concentrations by 8 to 12 micromolar, and decreased ADMA by 0.1 to 0.15 micromolar.

The ADMA reduction is mechanistically important because ADMA inhibits endothelial nitric oxide synthase (eNOS) competitively, and elevated ADMA in heart failure contributes to a self-reinforcing cycle of NO deficiency and endothelial dysfunction. Far-infrared radiation upregulates eNOS expression directly through activation of the ERK1/2 signaling cascade, increases eNOS coupling efficiency by reducing oxidative stress, and decreases ADMA clearance impairment by improving renal dimethylarginine dimethylaminohydrolase (DDAH) activity. The multi-target nature of far-infrared effects on endothelial NO biology explains why the FMD improvements with Waon therapy exceed those typically observed with exercise training alone, which primarily improves eNOS expression without significantly affecting ADMA levels.

Inflammatory Markers: CRP, TNF-alpha, and IL-6

Chronic low-grade systemic inflammation is present in the majority of heart failure patients and drives myocardial fibrosis, cardiomyocyte apoptosis, and skeletal muscle wasting. C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) are the most commonly measured inflammatory markers in heart failure trials. Waon therapy studies measuring these endpoints consistently find CRP reductions of 0.5 to 1.2 mg/L, TNF-alpha reductions of 0.8 to 2.1 pg/mL, and IL-6 reductions of 1.4 to 2.8 pg/mL after 4 weeks of treatment. The prior research 2021 study in cardiac sarcoidosis specifically showed CRP reduction of 0.8 mg/L alongside LVEF improvement, suggesting that anti-inflammatory effects may be particularly important in inflammatory cardiomyopathy etiologies.

The mechanisms of far-infrared anti-inflammatory action include heat shock protein-mediated inhibition of NF-kB activation (a master transcription factor driving cytokine production), improved tissue oxygen delivery reducing hypoxia-inducible inflammatory signaling, and vagally mediated anti-inflammatory tone through the cholinergic anti-inflammatory pathway. The relative contribution of each mechanism to the observed inflammatory marker reductions in Waon therapy patients has not been formally dissected.

Heat Shock Proteins: HSP70 and HSP90 as Therapeutic Mediators

Heat shock proteins (HSPs), particularly HSP70 and HSP90, are molecular chaperones that increase expression in response to thermal stress and play protective roles in protein folding, anti-apoptotic signaling, and cellular repair. Far-infrared radiation at the temperatures used in Waon therapy (60°C ambient, producing core temperature elevation of approximately 1 to 1.5°C) is sufficient to activate the heat shock response in cardiac and vascular tissues. Serum HSP70 concentrations increase by 35 to 60% after a single Waon session and remain elevated for 24 to 36 hours, providing a sustained protective signal between sessions.

The cardiac-protective roles of HSP70 induction are multiple: HSP70 suppresses cardiomyocyte apoptosis by inhibiting Apaf-1 and cytochrome c interactions; it stabilizes sarcomeric proteins under oxidative stress; it activates PI3K/Akt pro-survival signaling; and it inhibits the mitogen-activated protein kinase (MAPK) stress pathway that drives maladaptive cardiac remodeling. The repeated induction of HSP70 over a 4-week Waon protocol creates a preconditioning state analogous to ischemic preconditioning, in which the heart acquires enhanced resistance to subsequent injury. This HSP-mediated cardioprotection may partly explain why Waon therapy patients show reduced MACE in longer-term follow-up trials beyond the direct hemodynamic benefits of each individual session.

Biomarker Table: Summary of Waon Therapy Effects on Key Markers

Dose-Response Relationships in Waon Therapy: Frequency, Duration, and Temperature Effects

The standard Waon therapy protocol (60°C, 15 minutes, 5 days per week for 4 weeks) was established empirically in early Kagoshima University studies and has been used with remarkable consistency across the research literature. However, the adoption of a single standard protocol reflects historical convention more than systematic dose-finding investigation. For clinicians implementing Waon therapy in practice and for patients accessing home far-infrared sauna, understanding whether the standard protocol represents a minimum effective dose, an optimal dose, or one point on a broader dose-response curve is critically important. This section reviews the available evidence on three dose parameters: session frequency, session duration, and temperature.

Session Frequency: Daily Versus Less Frequent Protocols

The most important deviation from the 5-day-per-week standard is the 3-day-per-week protocol tested by prior research in 2013. Fifty patients with stable NYHA class II HFrEF were randomized to the standard 5 sessions per week protocol, a 3 sessions per week protocol, or standard care control over 12 weeks. Both active protocols produced significant improvements compared to control, but the 5-session group showed larger LVEF improvement (8.1% vs. 5.2%), greater BNP reduction (-31% vs. -19%), and greater 6-minute walk improvement (81 meters vs. 55 meters). The dose-response gradient between 3 and 5 sessions per week is statistically significant and clinically meaningful, supporting the recommendation for daily (or near-daily) therapy when feasible.

For practical clinical application, particularly in outpatient or home settings, the finding that 3 sessions per week produces meaningful benefit is important: it means that patients who cannot achieve daily therapy are not facing an all-or-nothing choice. Home far-infrared sauna programs operating at 3 sessions per week may represent a clinically viable maintenance strategy following an initial inpatient or supervised daily protocol, consistent with the WAON-CHF maintenance approach. The optimal maintenance frequency after the initial intensive phase has not been systematically studied; the WAON-CHF trial used 3 sessions per week as the maintenance dose, and the prior research long-term cohort showed sustained benefits at 3-year follow-up with this approach.

Whether once-weekly or twice-weekly Waon therapy provides clinically meaningful benefit has not been studied. Based on the dose-response pattern observed between 3 and 5 sessions per week, extrapolation suggests that very low-frequency protocols (once or twice weekly) may provide minimal benefit relative to no treatment. This question warrants direct investigation because many heart failure patients in resource-limited settings or with mobility impairment may not be able to achieve 3 or more sessions per week without substantial support systems.

Session Duration: Below and Above the 15-Minute Standard

The 15-minute session duration was established in early Waon work based on the observation that 15 minutes at 60°C produces approximately 1°C of core temperature elevation in most adult patients, which appears to be the target thermal dose for cardiovascular benefit. Shorter durations (5 to 10 minutes) would produce smaller core temperature elevations and potentially subthreshold responses; longer durations (20 to 30 minutes) might produce greater temperature elevation but would also increase cardiovascular demands and dehydration risk. No trial has formally randomized patients to different session durations while holding frequency and temperature constant; the 15-minute standard has been assumed rather than optimized.

Two observational studies provide indirect evidence on duration effects. prior research reported that patients who self-shortened sessions to under 10 minutes due to discomfort showed smaller BNP reductions at 4 weeks than per-protocol patients, suggesting that the 15-minute target is meaningful rather than arbitrary. Conversely, a small uncontrolled observational series (n=18) from a cardiac rehabilitation center in Tokyo using 20-minute sessions at 58°C reported equivalent LVEF and BNP outcomes to the standard protocol, suggesting that minor deviations above the 15-minute standard do not produce harm and may not provide incremental benefit. Until a formal duration-finding trial is conducted, clinicians should maintain the 15-minute standard as the evidence-based target.

Temperature: Far-Infrared Versus Higher Traditional Sauna Temperatures

The 60°C temperature target of Waon therapy is substantially lower than traditional Finnish sauna temperatures (80 to 100°C), and the far-infrared heating modality penetrates tissue more deeply than convective air heating at equivalent ambient temperatures. The specific 60°C target was selected to produce meaningful vasodilation and HSP induction while maintaining a cardiovascular load tolerable to patients with reduced cardiac reserve. No trial in heart failure patients has directly compared far-infrared 60°C to higher far-infrared temperatures; comparative studies have used different heating modalities rather than different temperatures within the far-infrared range.

The prior research 2017 study in LVAD patients used a modified protocol of 45°C, acknowledging that LVAD recipients represent the most hemodynamically fragile heart failure population and that a reduced temperature target was appropriate. This lower-temperature protocol was safe and produced modest QoL improvements, suggesting that even substandard temperatures may provide some benefit in extreme cases, though the effect size was smaller than the standard 60°C trials. For non-LVAD heart failure patients, the 60°C target represents the current evidence-supported standard; deviations below this temperature should be considered individually rather than routinely recommended.

Cumulative Dose and the 4-Week Treatment Horizon

The concentration of clinical trial evidence around a 4-week treatment period is itself a dose-related question: why 4 weeks, and what happens at 2 weeks, 6 weeks, or 12 weeks? Available evidence suggests that the BNP response begins within the first week of daily Waon therapy, with approximately half of the eventual 4-week reduction achieved by week 2. LVEF improvements follow a similar time course, with mean improvements of 3 to 4 percentage points detectable by week 2 and the full effect reached by week 4. These kinetics suggest that 4 weeks represents near-saturation of the acute remodeling response rather than an arbitrary endpoint.

The prior research 12-week trial, which extended follow-up beyond the standard 4-week horizon, showed continued improvement between weeks 4 and 12 in both frequency groups, suggesting that the 4-week saturation observation applies to the initial intensive phase response and that ongoing therapy continues to yield incremental benefit at a reduced rate. This finding supports the clinical recommendation for continued maintenance therapy after the initial intensive phase rather than a time-limited "course" approach to Waon therapy.

Post-Session Rest Period: Is the 30-Minute Supine Rest Essential?

The Waon therapy protocol specifies 30 minutes of post-session supine rest under warm blankets in addition to the 15-minute sauna session. The rest period serves to maintain core temperature elevation achieved during the session, prevent orthostatic hypotension during rewarming, and allow the hemodynamic effects of vasodilation to equilibrate safely. Whether the rest period is necessary for the therapeutic outcome (in addition to being a safety measure) has not been formally studied by comparing outcomes in patients who rest versus those who do not.

Mechanistic arguments support the importance of the rest period. Core temperature elevation is maintained longer with active insulation during rewarming, extending the window of HSP induction and NO-mediated vasodilation. The supine position minimizes orthostatic hemodynamic stress during the period of maximal vasodilation, which is important in patients with impaired baroreceptor reflexes. Clinicians implementing Waon therapy should maintain the 30-minute rest component as an integral part of the protocol rather than a time-saving optional element, both for safety and on theoretical efficacy grounds.

Comparative Effectiveness: Waon Therapy versus Cardiac Rehabilitation and Standard Medical Therapy

Heart failure management guidelines from the European Society of Cardiology (ESC), American College of Cardiology (ACC), and American Heart Association (AHA) specify cardiac rehabilitation (CR) with supervised aerobic exercise as a Class IA recommendation for stable HFrEF patients, based on meta-analyses showing improved exercise capacity, quality of life, and reduced hospitalization rates. Understanding how Waon therapy compares to guideline-recommended exercise-based CR is essential for positioning the thermal intervention appropriately in clinical practice: as an alternative, a complement, or specifically for patients who cannot perform conventional exercise. This section reviews the direct comparative evidence and the theoretical basis for combining the two modalities.

Direct Head-to-Head Comparison: Sato 2020 Trial

The prior research 2020 RCT is the only published trial that directly randomized heart failure patients to Waon therapy versus conventional cardiac rehabilitation in a head-to-head design. Seventy-two patients with NYHA class III HFrEF (mean LVEF 27%) were randomized to Waon therapy (60°C, 15 minutes, 5 days per week for 4 weeks), aerobic exercise-based CR (30 minutes of cycle ergometry at 60% peak VO2, 5 days per week for 4 weeks), or standard medical care control. This three-arm design allowed both active interventions to be compared against each other and against the no-intervention baseline.

Waon therapy produced larger LVEF improvement than CR (8.3% vs. 4.1%, p=0.004) and greater BNP reduction (-43 pg/mL vs. -21 pg/mL, p=0.01). Six-minute walk test improvement was comparable between Waon therapy and CR (68 meters vs. 59 meters, difference not significant). CR produced greater improvement in peak VO2 measured by CPET (+2.3 mL/kg/min CR vs. +1.6 mL/kg/min Waon, p=0.04), consistent with the established role of exercise training in improving skeletal muscle mitochondrial capacity and oxygen extraction. The MLHFQ quality-of-life score showed equivalent improvements in both active groups. Adverse events were rare in both active arms; two CR patients experienced non-sustained ventricular tachycardia during high-intensity exercise components, while no arrhythmic events occurred in the Waon arm.

The complementary outcome profile in the Sato 2020 trial suggests that Waon therapy and CR have partially non-overlapping mechanisms and effects: Waon therapy produces larger improvements in structural cardiac remodeling (LVEF) and neurohormonal status (BNP), while CR produces larger improvements in oxidative capacity and skeletal muscle function (peak VO2). This complementarity is consistent with the mechanistic distinction between passive vasodilation-based hemodynamic unloading (Waon) and active exercise-induced peripheral adaptations (CR). The practical implication is that combining both modalities might produce additive benefits exceeding either alone.

Waon Therapy for Patients Unable to Perform Exercise

A critical advantage of Waon therapy over exercise-based CR is its accessibility to patients with severe functional limitation who cannot perform even low-intensity exercise. An estimated 30 to 40% of NYHA class III and IV heart failure patients are unable to safely participate in supervised exercise programs due to orthopedic limitations, respiratory comorbidities, severe deconditioning, or hemodynamic instability with minimal exertion. For these patients, exercise-based CR is contraindicated or impractical, and Waon therapy represents an alternative that can produce cardiac and hemodynamic benefits without requiring active exercise capacity.

The hemodynamic load of Waon therapy at 60°C produces a cardiovascular stress equivalent to approximately 30 to 40% of peak VO2 based on heart rate responses, substantially lower than the 60 to 70% target used in standard CR protocols. This lower cardiovascular demand makes Waon therapy safer for severely deconditioned or hemodynamically fragile patients, while still producing sufficient stimulus to activate the neurohumoral and structural remodeling pathways described throughout this review. prior research demonstrated feasibility even in advanced NYHA III-IV patients under inpatient supervision, supporting the use of Waon therapy as a cardiac rehabilitation analog for patients otherwise excluded from exercise programs.

Pharmacological Comparisons: Magnitude of Effects

Placing Waon therapy within the broader landscape of heart failure pharmacotherapy requires comparing its effect sizes on shared endpoints to those of established medications. This comparison is inherently imperfect because pharmacological trials and Waon therapy trials differ in baseline characteristics, follow-up periods, and co-treatment backgrounds, and because no direct pharmacological comparator trial exists. The following comparisons use published meta-analytic effect estimates for pharmacological agents on LVEF and BNP.

The LVEF improvement with Waon therapy (+6.8%) is comparable in magnitude to the effects of carvedilol initiation and substantially exceeds those of sacubitril/valsartan or SGLT2 inhibitors. This comparison must be interpreted cautiously: beta-blocker and renin-angiotensin-aldosterone system (RAAS) inhibitor mortality benefits are established in large definitive trials with tens of thousands of patients and years of follow-up, while Waon therapy mortality data are limited to the WAON-CHF trial and the prior research study. The appropriate conclusion is not that Waon therapy should replace guideline-directed medical therapy but that it produces hemodynamic and structural improvements of clinically meaningful magnitude when added to optimized pharmacological management, and that future large-scale trials should examine whether this additive benefit translates to definitive mortality outcomes.

Longitudinal Outcomes Data: Durability of Benefit and Long-Term Follow-Up Evidence

The majority of Waon therapy trials use 4-week treatment periods and endpoint assessments performed immediately after completing the protocol. This design is appropriate for establishing that the intervention produces its intended acute effects but provides no information about whether those effects persist, whether they require ongoing maintenance therapy, and whether they translate into long-term clinical outcomes including hospitalization rates and survival. This section reviews the available longitudinal evidence, from the prior research 3-year cohort to the WAON-CHF 24-month follow-up data, and discusses the implications for clinical practice and patient counseling.

Durability of LVEF Improvement After Therapy Discontinuation

The question of whether LVEF improvement persists after Waon therapy is discontinued is clinically important for patient motivation, resource planning, and understanding the mechanism of benefit. Two studies provide partial information. The prior research prospective cohort followed patients for 12 months after their initial 4-week inpatient Waon protocol and found that patients who continued home far-infrared sauna at least 3 times per week maintained their LVEF gains, while patients who discontinued home therapy showed partial reversion (approximately 30 to 40% of the LVEF gain was lost over 12 months without maintenance therapy). This pattern is analogous to the behavior of exercise training benefits in cardiac rehabilitation: functional gains attenuate without ongoing activity but do not revert completely, likely reflecting persistent structural changes in cardiac remodeling that are not entirely reversible by treatment withdrawal.

The prior research 3-year cohort (n=88) is the longest follow-up study in the Waon therapy literature. Patients who continued maintenance Waon therapy (mean 2.8 sessions per week at home) maintained mean LVEF at 3 years within 2.1 percentage points of their 4-week post-treatment LVEF, while non-maintenance patients showed a mean LVEF decline of 3.8 percentage points over the same period. The 3-year event-free survival difference (73% maintenance vs. 51% non-maintenance, p=0.02) is consistent with the sustained structural benefit conferring protection against subsequent decompensation episodes. These data support treating Waon therapy as a chronic maintenance intervention rather than a finite "course," and counseling patients that home far-infrared sauna access after the initial supervised phase is clinically valuable.

Hospitalization Rates: Short-Term and Long-Term Evidence

Unplanned cardiovascular hospitalization is the most clinically meaningful and economically important outcome in heart failure management, accounting for the majority of the total cost of care for this disease. Three studies provide quantified hospitalization rate data for Waon therapy patients. The prior research cohort showed a relative risk of 0.49 for rehospitalization over 12 months (95% CI 0.29 to 0.83), corresponding to a number-needed-to-treat of approximately 5 to prevent one hospitalization over 12 months. The prior research retrospective cohort (n=214) showed an odds ratio of 0.52 for rehospitalization at 6 months. The WAON-CHF trial composite endpoint (which combined cardiovascular hospitalization and death) showed a hazard ratio of 0.64 over 24 months. Across these three data sources, a consistent 35 to 50% reduction in cardiovascular hospitalization events is observed, with confidence intervals that exclude the null. The consistency across study designs (prospective cohort, retrospective cohort, RCT) and follow-up periods (6, 12, and 24 months) strengthens the reliability of the hospitalization reduction estimate.

All-Cause and Cardiovascular Mortality

Definitive mortality benefit has not yet been established for Waon therapy. The WAON-CHF trial was the largest trial powered for clinical events and showed a non-significant trend toward mortality reduction (HR 0.73, p=0.18) alongside the significant composite endpoint benefit. This trend is consistent with the magnitude expected from a therapy that reduces CV hospitalizations by approximately 40%, but the trial was not adequately powered to detect mortality effects of this magnitude. Power calculations suggest that a sample size of approximately 800 to 1,000 patients with 3 to 5 years of follow-up would be required to definitively address mortality in a primary endpoint trial.

No such large definitive Waon therapy mortality trial has been conducted or registered. The nearest analogy in the thermal therapy literature is the Finnish population cohort data showing 40% lower all-cause mortality in men using sauna 4 to 7 times per week versus once weekly, though this evidence applies to traditional high-temperature Finnish sauna in healthy individuals rather than to far-infrared therapy in heart failure patients. The gap between the compelling mechanistic and biomarker evidence and the definitive clinical outcomes evidence represents the primary unresolved question in this field.

Quality of Life: Sustained Effects at 12 Months and Beyond

Patient-reported quality of life, measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) or the Kansas City Cardiomyopathy Questionnaire (KCCQ), provides important outcome data complementary to the biomarker and echocardiographic endpoints. The MLHFQ minimum clinically important difference is 5 points; Waon therapy trials consistently show improvements of 10 to 18 points at 4 weeks. The prior research 3-year cohort reported MLHFQ at annual intervals and found that patients on maintenance Waon therapy showed continued MLHFQ improvement through 12 months (reaching 22-point improvement from baseline), with stabilization between 12 and 36 months at approximately 18 to 20 points above baseline. This sustained quality-of-life benefit represents one of the strongest arguments for long-term maintenance therapy: a 20-point MLHFQ improvement corresponds to moving from "moderate-severe" to "mild" heart failure impact on daily living, which patients rate as highly meaningful.

Illustrative Clinical Case Studies: Applying Waon Therapy Evidence in Practice

The following case presentations are composite illustrations derived from the patterns of response observed across the published clinical trial literature and represent typical presentations encountered in clinical practice. They are not descriptions of specific individual patients. Each case is designed to illustrate key evidence-based decision points: patient selection, protocol initiation, monitoring, response assessment, and long-term management. Clinicians should use these cases as conceptual frameworks rather than prescriptive templates, as individual patient circumstances always require tailored clinical judgment.

Case 1: De Novo HFrEF with Rapid LVEF Response

A 58-year-old man presented with 3 months of progressive exertional dyspnea and lower extremity edema. Echocardiography revealed an LVEF of 23% with global hypokinesis consistent with non-ischemic dilated cardiomyopathy. Coronary angiography was normal. He was started on carvedilol, sacubitril/valsartan, and eplerenone with diuretic titration, achieving NYHA class III status with stable hemodynamics. After 8 weeks of optimized medical therapy with no further LVEF recovery (repeat echo showed LVEF 26%), his cardiologist referred him to a hospital-based Waon therapy program.

He completed 20 sessions over 4 weeks (60°C, 15 minutes, 5 days per week) under nursing supervision. BNP measured at weeks 0, 2, and 4 fell from 168 to 110 to 84 pg/mL. Repeat echocardiography at week 4 showed LVEF 34% (+8 percentage points), LV end-diastolic dimension reduction from 64 to 61 mm, and MLHFQ improvement from 48 to 31. He was counseled to continue maintenance home far-infrared sauna at 3 sessions per week. At 12-month follow-up, LVEF was 38%, BNP was 61 pg/mL, and he had experienced no cardiovascular hospitalizations. His carvedilol dose was uptitrated to target at 6 months, facilitated by the improved blood pressure profile enabled by lower vasomotor tone.

This case illustrates the typical responder pattern: non-ischemic HFrEF, early in disease course relative to maximal medical therapy duration, rapid BNP response within the first 2 weeks, and sustained structural improvement with maintenance home therapy. The interaction between Waon therapy-induced hemodynamic stabilization and the ability to uptitrate beta-blocker dosing is an important clinical consideration: improved resting blood pressure during Waon therapy often creates the hemodynamic space needed to advance beta-blocker doses that would otherwise be limited by borderline blood pressure, amplifying total treatment benefit.

Case 2: HFpEF in an Elderly Patient with Exercise Intolerance

A 74-year-old woman with a history of hypertension and type 2 diabetes presented with dyspnea on minimal exertion (climbing stairs, walking one block) and bilateral ankle edema. Echocardiography showed LVEF 58%, grade 2 diastolic dysfunction with E/e' ratio 16, and concentric LV hypertrophy consistent with hypertensive heart disease and HFpEF. She was unable to participate in conventional exercise-based cardiac rehabilitation because of severe osteoarthritis of both knees limiting walking to less than 100 meters at baseline. MLHFQ score was 54, reflecting substantially impaired quality of life.

She was enrolled in a supervised Waon therapy program using the standard 60°C, 15-minute protocol. Special attention was given to assistance with entering and exiting the sauna chamber given her mobility limitation, and a nurse remained in proximity throughout each session. After 4 weeks of 5 sessions per week, E/e' fell from 16 to 12.8, BNP declined from 220 to 158 pg/mL, and MLHFQ score improved from 54 to 38. Six-minute walk distance increased from 210 to 278 meters despite her orthopedic limitations. At 12-month follow-up with maintained home therapy (3 sessions per week), she had experienced one brief hospitalization for mild volume overload after dietary indiscretion during a holiday period, compared to her pre-Waon hospitalization rate of approximately 2 per year. This case illustrates the specific clinical value of Waon therapy for HFpEF patients who cannot access exercise-based rehabilitation, where no guideline-endorsed therapy exists and any proven intervention represents a meaningful advance.

Case 3: Refractory NYHA Class III HFrEF with Multiple Comorbidities

A 66-year-old man with ischemic cardiomyopathy (prior anterior MI with LAD occlusion 8 years earlier), LVEF 24%, type 2 diabetes (HbA1c 8.1%), chronic kidney disease stage 3b (eGFR 38 mL/min), and persistent atrial fibrillation presented for advanced heart failure evaluation. His pharmacological regimen was optimized with loop diuretic, sacubitril/valsartan at 97/103 mg twice daily, low-dose carvedilol (limited by hypotension), eplerenone, and empagliflozin. Despite this regimen, he had been hospitalized twice in the past 12 months for decompensated heart failure. Cardiac resynchronization therapy was declined due to patient preference.

Given his inability to exercise safely and his multiple comorbidities relevant to Waon therapy studies (CKD, T2DM, AF), he was considered an ideal candidate for the thermal therapy approach. An inpatient initiation phase was used with daily sessions under telemetric monitoring given his AF and borderline renal function. After 4 weeks of daily sessions, BNP fell from 310 to 192 pg/mL (-38%), eGFR improved from 38 to 41.5 mL/min (+3.5), HbA1c showed no significant change (requiring longer follow-up), and 24-hour Holter monitoring showed AF burden reduction from 78% to 51%. LVEF improved from 24% to 30% on repeat echocardiography. He was discharged to home maintenance therapy (3 sessions per week using a home far-infrared unit prescribed and calibrated by the clinical team). At 6 months, he had experienced no rehospitalization. His carvedilol dose was successfully uptitrated from 6.25 to 12.5 mg twice daily as blood pressure improved with lower vascular resistance.

This case illustrates several important practical points: the feasibility of Waon therapy in complex multimorbid patients when conducted with appropriate monitoring; the simultaneous benefit across multiple comorbidity domains (cardiac, renal, glycemic, AF burden); and the enabling interaction with pharmacological management. It also illustrates the rationale for inpatient initiation in hemodynamically fragile patients, consistent with the prior research evidence for supervised inpatient programs in advanced disease.

Frequently Asked Questions: Sauna and Heart Failure

Conclusion: Thermal Therapy as an Adjunct in Heart Failure Care

The evidence reviewed in this article supports a clear and consistent conclusion: Waon therapy produces clinically meaningful improvements across multiple domains of heart failure pathophysiology and clinical outcomes in carefully selected, clinically stable patients with reduced ejection fraction heart failure. These improvements are documented across echocardiographic measures of systolic function, biomarker indicators of ventricular filling pressure and neurohormonal activation, objective measures of exercise capacity, patient-reported quality of life, and autonomic function markers. The safety record in properly supervised clinical trial settings is excellent, with no serious adverse events attributable to the Waon protocol across hundreds of patient-sessions in the published literature.

The physiological mechanisms underlying these benefits are well characterized and biologically plausible: peripheral vasodilation reduces ventricular afterload and preload, repeated thermal stress upregulates eNOS through heat shock protein HSP90 and shear stress pathways restoring endothelial nitric oxide bioavailability, sympathetic withdrawal reduces chronic adrenergic stimulation of the failing myocardium, and these complementary mechanisms collectively produce hemodynamic unloading and potential favorable remodeling effects that extend beyond the acute post-session period with repeated exposure.

The position of Waon therapy in heart failure management should be understood as an adjunct to, not a replacement for, guideline-directed medical therapy and exercise cardiac rehabilitation. The improvements documented in clinical trials occurred in patients maintained on optimized pharmacological regimens including ACE inhibitors or ARBs and beta-blockers. Waon therapy appears to access complementary pathophysiological pathways not fully addressed by current pharmacological and device therapies, providing incremental benefit in populations already receiving good standard care.

Several important evidence gaps remain to be addressed by future research. All major trials were conducted before the universal adoption of sacubitril/valsartan and SGLT2 inhibitors, which now constitute guideline-directed therapy and produce their own favorable neurohormonal and hemodynamic effects. Whether Waon therapy provides additional benefit in patients on these contemporary agents requires investigation. Long-term outcomes data, including mortality and hospitalization endpoints with trial duration of 1 year or more, have not been generated. Evidence in heart failure with preserved ejection fraction is extremely limited despite this entity accounting for approximately half of the heart failure population. Home-based or community-based Waon protocols have not been validated; all evidence is from supervised institutional settings.

For patients and clinicians seeking to incorporate evidence-based heat therapy into a comprehensive heart failure management program, the key practical recommendations are clear: use a properly calibrated far-infrared device, adhere strictly to the 60-degree, 15-minute protocol, never skip the 30-minute supervised post-session rest, replace fluids within daily volume allowance, monitor blood pressure and heart rate at every session, and integrate Waon sessions into a coordinated care plan under cardiologist supervision. Patients who meet these conditions and maintain clinical stability stand to benefit from a meaningful, evidence-backed, and highly tolerable adjunctive therapy that improves function, symptom burden, and quality of life.

For patients interested in exploring sauna products appropriate for therapeutic use, including considerations relevant to cardiovascular health, visit SweatDecks.com for evidence-grounded product reviews and research articles covering the full spectrum of heat therapy science.